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 TIIVISTELMÄ 
Verisuonten uudismuodostus eli angiogeneesi on tärkeä prosessi yksilönkehityksen 
aikana. Myös monissa eri sairauksissa, kuten syövässä, angiogeneesi tuottaa 
verisuonia, jotka ylläpitävät syöpäkasvaimen kasvua ja mahdollistavat etäpesäkkeiden 
muodostumista muualle kudoksiin (metastaasi). Vaskulaariendoteelikasvutekijä 
(VEGF) ja angiopoietiinikasvutekijät (Ang1 ja Ang2) säätelevät veri- ja imusuonten 
muodostusta suonen sisäpinnan endoteelisolujen reseptorityrosiinikinaasien (VEGF-
reseptori ja angiopoietiinireseptorit Tie1 ja Tie2) välityksellä. VEGF- ja Ang2-
kasvutekijät lisäävät verisuonten versomista ja läpäisevyyttä, kun taas Ang1 aktivoi 
Tie2-reseptorin endoteelisolujen välisissä liitoksissa, mikä vähentää endoteelin 
läpäisevyyttä. Verisuonten kasvua estäviä lääkkeitä, jotka estävät VEGF-kasvutekijän 
toimintaa (anti-angiogeneesilääkkeet), on käytetty useiden syöpien hoidossa noin 10 
vuoden ajan. Viime vuosien aikana levinneen eli metastasoivan munuaissyövän 
hoidoissa on saatu tuloksia lääkkeillä, jotka estävät mm. VEGF-kasvutekijäreseptoria 
ja VEGF-kasvutekijän aiheuttamaa angiogeneesiä. Usein hoidon aloituksen jälkeen 
syöpä kuitenkin uusiutuu. Tämän takia uusia Ang-Tie kasvutekijäreittiin 
kohdennettuja lääkkeitä on kehitteillä. Lisäksi on pyritty löytämään ns. 
biomarkkereita, joiden perusteella hoidot voitaisiin kohdentaa niistä parhaiten 
hyötyville syöpäpotilaille. 
Tässä tutkimuksessa tutkittiin molekyylitason mekanismeja, jotka säätelevät Ang-Tie-
signaalinvälitysreitin toimintaa verisuonien endoteelisolujen välisissä liitoksissa ja 
vuotavassa syöpäkasvaimen verisuonistossa, sekä Ang2-kasvutekijän ilmentymistä 
metastasoivan munuaissyöpäkasvaimen primäärituumorissa ja sen potentiaalia 
biomarkkerina anti-angiogeneesihoidoissa. 
Tässä tutkimuksessa osoitettiin, uusi funktio Tie1-reseptorille. Havaitsimme, että 
angiopoietiinit aktivoivat Tie2-reseptoria Tie1-reseptorin välityksellä, ja tämä 
vuorovaikutus ja reseptorien aktivaatio on riippuvainen α5β1-integriinistä. Tie1-
reseptorin poisto endoteelisoluista shRNA-välitteisesti vähensi Tie2-reseptorin 
aktivaatiota ja aiheutti Tie2-reseptorin siirtymisen pois solun pinnalta. FRET, FLIM 
ja TCSPC-FLIM mikroskopiaa käyttämällä osoitettiin Tie1- ja Tie2- reseptorien 
interaktio endoteelisolujen välisissä liitoksissa, ja tämä interaktio oli riippuvainen β1-
integriinistä. Estämällä β1-integriinin ilmentyminen saatiin estettyä myös Tie 
reseptorien angiopoietiinivälitteinen aktivaatio, ja aktivoituneen Tie reseptorin 
käynnistämät signalointireitit. Lisäksi Tie1-poistogeenisessa hiirimallissa osoitettiin, 
että Tie1 reseptori vaaditaan Ang1- ja Ang2- väitteisiin signalointiin ja verisuonien 
uudismuodostumiseen.  
Ang2-kasvutekijän määrä kohoaa seerumissa useissa eri sairauksissa, kuten syövässä. 
Tässä tutkimuksessa tutkittiin Ang2 vaikutusta etäpesäkkeiden muodostumiseen 
hiiren tuumorimalleissa. Tutkimuksessa osoitettiin, että Ang2-kasvutekijän 
siirtogeenivälitteinen ilmentäminen hiiressä lisäsi etäpesäkkeiden muodostumista 
keuhkoihin. Vastaavasti, Ang2-kasvutekijän estäminen vasta-aineella esti 
etäpesäkkeiden muodostumista ja paransi endoteelisolujen välisiä liitoksia. 
Soluviljelyssä endoteelisoluissa osoitettiin, että Ang2-kasvutekijän toimintaa estävät 
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vasta-aineet johtivat Ang2-Tie2 signalointikompleksin siirtymisen solun pinnalta 
solun sisälle, estäen tämän toimintaa. 
Korkeat seerumin Ang2 tasot ennustavat lyhentynyttä elinikää useissa syövissä, mutta 
Ang2-kasvutekijän ilmentymistä syöpäkasvaimessa ja sen mahdollista korrelaatiota 
kliiniseen hoitovasteeseen anti-angiogeneesihoitojen aikana ei ole tutkittu. Tässä 
tutkimuksessa määritettiin immunohistokemiallisella värjäyksellä Ang2-kasvutekijän 
ilmentyminen levinneen munuaissyövän primäärituumoreista, sekä verisuonten että 
jakautuneiden syöpäsolujen määrät. Ang2 ilmeni kasvaimen verisuonien 
endoteelisoluissa, ja korkea verisuonten ja Ang2-kasvutekijän määrä lisäsivät 
potilaiden todennäköisyyttä hyötyä sunitinib-hoidosta (P = 0.002). Matala 
jakaantuvien syöpäsolujen määrä ennusti merkittävästi potilaiden 
kokonaiselossaoloajan pidentymistä (P = 0.015). Toisessa potilasaineistossa, jossa 
potilaat eivät saaneet anti-angiogeneesihoitoa, korkea Ang2 määrä kasvaimen 
verisuonistossa ennusti pidentynyttä potilaiden kokonaiselossaoloaikaa. 
Yhteenvetona tämän tutkimuksen tulokset osoittavat, että Tie1- ja Tie2-reseptorien 
vuorovaikutus vaaditaan endoteelisolujen angiopoietiinivasteeseen ja verisuonien 
muokkaukseen, ja että Tie1-reseptori säätelee Tie2 liikkumista solussa. Osoitimme 
myös, että Ang2-kasvutekijää estävät vasta-aineet estävät Ang2 sitoutumista Tie2-
reseptoriin, ja aiheuttavat Tie2-Ang2 -signaalikompleksin siirtymisen solun sisälle, 
estäen kompleksin toiminnan. Kokeellisissa syöpäkasvaimissa Ang2-vasta-aineen 
käyttö vähensi merkittävästi etäpesäkkeiden muodostumista keuhkoihin, mikä johtui 
osaltaan vasta-aineen verisuonia tiivistävästä vaikutuksesta. Lisäksi osoitimme, että 
Ang2 ilmentyy munuaissyöpäkasvaimen verisuonistossa ja korkea Ang2-pitoisuus 
ennustaa hoitovastetta sunitinib-hoidolle. Nämä tulokset tuovat uutta tietoa Ang-Tie 
systeemin toiminnasta endoteelisoluissa ja sen vaikutuksesta syöpäkasvaimen 
leviämiseen verisuoniston kautta. 
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 ABSTRACT 
Angiogenesis, the growth of new blood vessels, is essential for embryonic 
development, but it is also involved in numerous human diseases, including cancer. 
Vascular endothelial growth factors (VEGFs) and their receptors (VEGFRs), as well 
as angiopoietin growth factors (Ang1, Ang2) together with their Tie1 and Tie2 
tyrosine kinase receptors are essential regulators of angiogenesis and 
lymphangiogenesis. These pathways also control vessel permeability, for example in 
endotoxemia. VEGF-targeted therapies have been in clinical use for more than a 
decade, whereas Ang-Tie targeted drugs are in clinical development for cancer, as well 
as neovascular and edema causing eye diseases. Renal cell carcinoma (RCC) is a 
highly vascular tumor, which is notoriously resistant to chemotherapy and in the 
majority of the cases to immunotherapy. In recent years, blocking of VEGF-driven 
angiogenesis has become the choice of therapy in the metastatic form of RCC 
(mRCC). However, problems with anti-angiogenic therapies are associated with drug 
related resistance, and biomarkers that would predict patient responses are lacking. 
In this study, we focused to uncover the molecular mechanisms of the Ang-Tie 
signalling system with relevance to tumor metastasis and endotoxemia. Second, we 
sought to investigate Ang2 expression in human mRCC, and its potential as a 
biomarker for anti-angiogenic therapies. 
We found that Tie1 is essentially required for angiopoietin signalling in the mature 
vasculature and for agonistic activity of Ang2, which was lost in inflammation. Using 
fluorescence resonance energy transfer (FRET), fluorescence lifetime imaging 
microscopy (FLIM) and time correlated single photon counting (TCSPC)-FLIM, we 
demonstrated angiopoietin induced interactions between Tie1 and Tie2 receptors in a 
distance less than 10 nm in intact endothelial cells (ECs). Tie receptor interactions 
occurred preferentially in endothelial cell-cell (EC-EC) junctions, and were dependent 
on the EC -extracellular matrix (ECM) adhesion receptor, β1-integrin. Short hairpin 
ribonucleic acid (shRNA) silencing of β1-integrin inhibited also Tie receptor 
activation and downstream signalling. Using live cell imaging we found that Tie1 
regulated Tie2 trafficking in ECs after angiopoietin stimulation. These results provide 
mechanistic explanations for the decreased angiopoietin signalling and vessel 
remodelling observed upon conditional deletion of Tie1 in the mouse endothelium. 
We also found, that Tie1 is essential for the agonist activity of Ang1 and autocrine 
Ang2 in vivo during vascular remodelling. In inflammatory conditions, the Tie1 
ectodomain was rapidly cleaved resulting in decreased Ang1 agonist activity and 
complete loss of autocrine Ang2 agonist activity, leading to impaired Tie2 signalling.  
Ang2 is induced by hypoxia in tumor ECs promoting angiogenesis. To understand 
Ang2 function in tumor progression, we investigated the effect of Ang2 on metastatic 
dissemination using tumor xenografts in mice. We found that Ang2 overexpression in 
transgenic mice decreased endothelial integrity in pulmonary capillaries and enhanced 
tumor metastasis to lungs, whereas lung metastasis was inhibited using Ang2-blocking 
antibodies (Abs). At the molecular level, Ang2-blocking Abs inhibited Ang2-Tie2 
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signalling by inducing internalization of the plasma membrane localized Ang2-Tie2 
complexes. 
Elevated circulating Ang2 levels have been reported to predict poor prognosis in 
certain human cancers, but the expression of Ang2 in the primary tumor or its 
significance for anti-angiogenic therapies have not been widely investigated. We 
developed a method to detect Ang2 in the vascular endothelium of human tumors. In 
the first patient cohort, we found that high pre-therapeutic Ang2 expression, especially 
when combined with high expression of endothelial marker CD31, was associated 
with a high clinical benefit rate (CBR) to first-line sunitinib therapy (P = 0.002). Low 
tumor cell proliferation marker Ki-67 expression was associated with significantly 
prolonged progression-free survival (PFS) (P = 0.009) and overall survival (OS) (P = 
0.015). In the second cohort high Ang2 expression in tumor vasculature was associated 
with prolonged OS in patients who received no systemic anti-angiogenic therapies. 
In summary, our results demonstrate that Tie1 is essential for angiopoietin signalling 
and vascular remodelling, by interacting with Tie2 and regulating the subcellular 
trafficking of Tie2. Second, a therapeutic anti-Ang2 Ab that promotes vessel integrity 
and inhibits tumor metastasis, works by inhibiting Ang2 binding to Tie2, and inducing 
the internalization of Ang2-Tie2 signalling complexes from ECs. Third, Ang2 is 
expressed in the vasculature of RCC tumors, correlating with clinical response to 
sunitinib and OS, calling for more thorough studies of Ang2 in human RCC. These 
results advance the current understanding of the function of the Ang-Tie pathway in 
the vasculature. 
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 INTRODUCTION 
Angiogenesis, the formation of new blood vessels, is essential for embryonic 
development and normal homeostasis, but it is also involved in numerous human 
diseases, such as in cancer. Tumor angiogenesis supports tumor growth and facilitates 
metastatic dissemination of tumor cells. Angiogenesis is a complex process, which is 
regulated by multiple growth factors and cytokines in concert with cell adhesion 
receptors, integrins. VEGFs and their receptors are master regulators of early blood 
and lymphatic vascular development. In addition, Ang1 and Ang2 growth factors 
regulate vascular development after mid-gestation via their endothelial receptor 
tyrosine kinases (RTKs) Tie2 and Tie1 (Augustin et al., 2009, Lohela et al., 2009, 
Eklund and Saharinen, 2013).  
Ang1 acts as an agonist inducing translocation and activation of Tie2 in EC-EC 
contacts resulting in EC stabilization and survival and in EC-EC contacts regulating 
EC migration (Saharinen et al., 2008). Depending on the context, Ang2 may act as a 
weak agonist or antagonist of Tie2, inhibiting Ang1-mediated Tie2 activation by 
competing for Tie2 binding (Maisonpierre et al., 1997, Yuan et al., 2009). However, 
the molecular mechanisms that determine how Ang1 and Ang2 activate Tie2 resulting 
in different signalling outcomes are not well understood. Tie1 is an orphan receptor 
with no known ligand, but angiopoietins can activate Tie1 via Tie2 interaction 
(Saharinen et al., 2005). The molecular function of Tie1 in angiopoietin signalling and 
downstream signalling proteins activated by Tie1 are also not well established.   
Ang2 expression is low under normal homeostasis, but elevated in numerous diseases, 
including cancer and inflammation (Eklund and Saharinen, 2013). High circulating 
Ang2 levels and increased Ang2 messenger ribonucleic acid (mRNA) expression have 
been found to predict for poor prognosis in breast cancer, melanoma and RCC (Sfiligoi 
et al., 2003, Helfrich et al., 2009, Wang et al., 2014). Also, Ang2 protein expression 
in the tumor tissue has also been reported (Sfiligoi et al., 2003), but the potential 
significance of Ang2 expression in response to targeted therapies has been only 
scarcely studied.  
Ample preclinical evidence has shown that blocking the Ang-Tie system inhibits 
tumor growth and tumor angiogenesis. Thus, the Ang-Tie system has become a target 
for second-generation anti-angiogenic therapies, which are currently in clinical phase 
II-III trials in many human cancers (Monk et al., 2014, Atkins et al., 2015). However, 
the signalling mechanisms of the Ang-Tie system in the tumor vasculature are 
incompletely understood, and the expression of the Ang-Tie pathway components in 
human cancer has not been largely investigated.  
RCC is a highly vascular tumor, which accounts for approximately 2-3 % of all adult 
malignancies, and has an increasing rate of incidence in many countries. RCC is highly 
resistant to chemotherapy and in the majority of the cases to traditional 
immunotherapy based on interferon-α. Increased knowledge of the molecular 
pathogenesis of RCC has established new targets in the disease management (Rini et 
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al., 2009). Sunitinib is a multi-targeted tyrosine kinase inhibitor (TKI) and widely used 
as a first-line therapy for mRCC. Previous studies have shown objective response rates 
(ORRs) to sunitinib in mRCC, however complete durable responses are rare (Motzer 
et al., 2006). To improve efficacy, investigational Ang1/Ang2 blocking peptibody has 
been combined in a clinical phase II RCC trial with sunitinib, and this combinational 
treatment suggested a potential clinical benefit (Atkins et al., 2015). 
Current anti-angiogenic drugs, which inhibit the growth of new blood vessels, have 
revolutionized the treatment of many human cancers, however, complete responses 
are rare, and most patients are either refractory or relapse after a few months of 
treatment. Furthermore, no clear guidelines exist for patient- or tumor-specific 
selection of anti-angiogenic therapeutic agents, and so far no established biomarkers 
for antiangiogenic therapies are in clinical use. Therefore, novel treatment modalities 
for cancer are urgently needed, as well as knowledge of the biomarkers for the 
selection of patients, who will benefit from the anti-angiogenic therapy.  
In this work, I have investigated signalling mechanisms of the Ang-Tie system, from 
the molecular level to the translational level, in order to better understand the 
mechanisms leading to vessel remodelling during inflammation, and in tumors and 
tumor metastasis. We show, that the orphan Tie1 is an essential component of the Ang-
Tie2 signalling pathway, of Tie2 trafficking and that it also mediates Tie1-Tie2 
interaction in EC-EC contacts in a β1-integrin depended manner. Also, we show that 
a therapeutic anti-Ang2 Ab inhibits tumor growth and metastasis, and provide a 
mechanism of Ab action, supporting the concept that anti-Ang2 Abs may have 
potential in clinical cancer therapies. At the translational level, we show that high 
endothelial Ang2 expression in the primary RCC tumor alone or when combined with 
high microvessel density (MVD) was associated with clinical benefit to sunitinb in 
mRCC patients. Results from another cohort of RCC patients, who received no 
targeted therapies, demonstrate that very high endothelial Ang2 expression in RCC 
tumor was associated with better OS. These studies highlight the need for more 
thorough investigations of Ang2 expression in human cancer. These findings have the 
potential to facilitate the future therapeutic targeting of the Ang-Tie system and its use 
as a biomarker in human disease. 
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 LITERATURE REVIEW 
1. Blood vasculature 
1.1.  Structure and functions of the blood vascular system 
Blood and lymphatic vasculatures form essential systems for the transport of 
substances in the body.  The blood vasculature transports oxygen, nutrients, 
macromolecules and cells into distant tissues and back to pulmonary circulation. The 
arterial blood circulation, formed by arteries and arterioles is connected via capillaries 
to the venous system formed by venules and veins. ECs are essential building blocks 
of blood and lymphatic vessels, forming the innermost layer of the vessels that faces 
the vessel lumen. ECs are surrounded by a vascular basement membrane (BM), which 
they share with mural cells, including vascular smooth muscle cells (SMCs) embedded 
in connective tissue around arteries and veins and pericytes, which are found in 
postcapillary venules and venules (Baluk et al., 2005). The perivascular cells provide 
vessel stabilizing signal (reviewed in Jeltsch et al., 2013). Pericytes also participate in 
the maturation and remodelling of the blood vascular system and critically regulate 
the blood brain barrier (Benjamin et al., 1998, Gerhardt and Betsholtz, 2003, Armulik 
et al., 2010). Capillaries consist almost exclusively of ECs (reviewed in Jeltsch et al., 
2013).  
The formation of new blood vessels from pre-existing vessels, called angiogenesis, is 
an important process in both physiological and pathological conditions. During 
angiogenesis, quiescent ECs undergo a switch to an activated state, including 
upregulation of metalloproteases that degrade the ECM to enable EC migration to the 
surrounding space and EC proliferation (Kumar et al., 2014). 
1.2.  Growth factor regulation of vascular endothelial cells 
1.2.1. VEGFs and VEGFRs 
VEGFs (VEGF-A, -B, -C, and -D and placental growth factor, (PlGF) and their 
receptors (VEGFR1, -2, and -3) are essential regulators of angiogenesis (Figure 1.). 
The VEGF family members are secreted, homodimeric glycoproteins, which include 
several isoforms produced by alternative exon splicing (Houck et al., 1991, Tischer et 
al., 1991) and post-translational modifications (Xiong et al., 1998). VEGF-A (VEGF) 
is a ligand for VEGFR2 and VEGFR1, VEGF-B and PlGF for VEGFR1, VEGF-C and 
VEGF-D for VEGFR3, although the fully processed form of VEGF-C can also bind 
to VEGFR2. 
VEGF exists in six isoforms (VEGF121, VEGF145, VEGF162, VEGF165, VEGF183, 
VEGF189, VEGF206 (Houck et al., 1991, Park et al., 1993, Poltorak et al., 1997, 
Vempati et al., 2014), which are generated via alternative splicing. VEGF expression 
is induced by the hypoxia-inducible factor-1α (HIF-1α) in hypoxic conditions (Brogi 
et al., 1996). VEGF is essential for normal blood vascular growth during embryonic 
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development, and lack of already one VEGF allele is lethal (Ferrara et al., 1996). 
VEGF is the major regulator of vasculogenesis and angiogenesis and it binds to 
VEGFR2 and VEGFR1 (de Vries et al., 1992, Terman et al., 1992, Millauer et al., 
1993, Quinn et al., 1993). Ligand binding to VEGFR2 stimulates its tyrosine 
phosphorylation leading to a strong angiogenic response (Waltenberger et al., 1994). 
Instead, VEGF binding to VEGFR1 induces a weak tyrosine kinase activity, and is 
required to supress excess angiogenesis (Ferrara, 2004). 
VEGF-B is expressed in tissues with high metabolic activity, such as in skeletal 
muscle and vascular SMCs, myocardium, brown adipose tissue, kidney and the brain 
(Olofsson et al., 1996, Lagercrantz et al., 1998, Aase et al., 1999, Bry et al., 2014). 
VEGF-B is structurally very similar to VEGF (Grimmond et al., 1996, Olofsson et al., 
1996). VEGF-B has a splicing site in exon six and it is expressed as two isoforms 
(Grimmond et al., 1996, Olofsson et al., 1996), which both bind to VEGFR1 and 
Neuropilin-1 (NRP-1), but not to VEGFR2 and VEGFR3 (Olofsson et al., 1998, 
Makinen et al., 1999). On the contrary to VEGF, hypoxia does no induce VEGF-B 
expression (Enholm et al., 1997). VEGF-B is not a strong inducer of angiogenesis 
(reviewed in Bry et al., 2014). It stimulates weakly sprouting angiogenesis, and 
overexpression of VEGF-B in the skin increased minimally blood vessel density 
(Karpanen et al., 2008). Vegf-b deficient mice and rats do not have pronounced 
vascular or developmental defects (Aase et al., 2001, Kivela et al., 2014). Instead, 
transgenic expression of Vegf-b induced the growth of coronary arteries and 
enlargement of myocardial capillaries (Karpanen et al., 2008, Bry et al., 2010). Both 
mice and rats expressing transgenic Vegf-b present cardiac hypertrophy and capillary 
enlargement (Karpanen et al., 2008, Li et al., 2008, Bry et al., 2010). In addition, 
overexpression of Vegf-b in mice increased the growth of new blood vessels in the 
infarcted and ischemic border zone in the heart (Li et al., 2008). VEGF-B is 
upregulated in certain cancers, such as RCC and colorectal cancer, but its function in 
human cancer remains unknown (Gunningham et al., 2001, Hanrahan et al., 2003).  
VEGF-C is required for the development of lymphatic vessels, and it is also a major 
regulator of lymphangiogenesis in adults. In addition, fully proteolytically processed 
VEGF-C can induce neovascularization of mouse cornea (Cao et al., 1998). VEGF-C 
binds to and activates VEGFR3 (Joukov et al., 1996). VEGF-C is proteolytically 
cleaved resulting in high affinity binding of VEGF-C to VEGFR3 and to VEGFR2 
(Joukov et al., 1997). Constitutive Vegf-c deficient mouse embryos die during 
embryonic period because of defective lymphatic vessel development leading to fluid 
accumulation in the tissue (edema). Mouse embryos heterozygous for Vegf-c have 
defective lymphatic vasculature and lymphedema, nevertheless they survive during 
embryonic development until adulthood (Karkkainen et al., 2004). VEGF-C is 
expressed by many tumor cells and tumor associated myeloid cells (reviewed in 
Karpanen and Alitalo, 2008). In tumors, VEGF-C expression induces 
lymphangiogenesis facilitating tumor cell intravasation into the vessel and lymphatic 
metastasis (Skobe et al., 2001). 
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VEGF-D is a second growth factor that stimulates lymphangiogenesis via binding to 
VEGFR3 and the NRP co-receptors, and it undergoes similar proteolytic cleavage as 
VEGF-C (Achen et al., 1998). VEGF-D can also promote tumor growth and 
angiogenesis by stimulating tumor lymphangiogenesis in mouse tumor models 
(Stacker et al., 2001).  
VEGFRs are type-V RTKs composed of an extracellular domain, a transmembrane 
region and an intracellular tyrosine kinase domain (Shibuya et al., 1990, Terman et 
al., 1991, Matthews et al., 1991) (Figure 1.). Extracellular domains of VEGFRs 
consist of seven immunoglobulin (Ig) homology domains (Terman et al., 1991), where 
the second Ig domain is required for ligand binding promoting receptor dimerization 
and the third domain is needed to strengthen ligand-receptor interaction (Joukov et al., 
1996, Leppanen et al., 2010).  
VEGFR1 (Flt-1) was the first RTK of the VEGFR family to be identified (de Vries et 
al., 1992), but its specific function is still unclear, because VEGFR1 can signal 
differentially depending on cell type and developmental stage (Ferrara, 2004). 
Recently published data in mouse embryonic stem cell derived-vessels lacking Vegfr1 
demonstrated that vessel branching was significantly decreased whereas initiation of 
vessel sprout and connectivity with other vessels was increased (Chappell et al., 2016). 
VEGFR1 is a receptor for the VEGF, VEGF-B and PlGF ligands (de Vries et al., 1992, 
Park et al., 1994, Olofsson et al., 1998) and it is upregulated in hypoxia via HIF-1α 
(Gerber et al., 1997). VEGFR1 is able to undergo alternative splicing resulting in a 
soluble form of VEGFR1, which can inhibit VEGF activity and signalling (Kendall 
and Thomas, 1993). VEGFR1 is essential during embryonic development and 
VEGFR1 deletion leads to overgrowth of endothelial-like abnormal cells within 
vascular lumens and embryonic death between E8.5 and E9.5 (Fong et al., 1995, Fong 
et al., 1999). Interestingly, mice lacking the VEGFR1 tyrosine kinase domain (Flt1TK-
/-) can still bind VEGF, and have normal vascular development indicating that 
VEGFR1 inhibits VEGF activity (Hiratsuka et al., 1998).  
VEGFR2 (kinase insert domain-containing receptor (KDR), human; fetal liver kinase 
1 (Flk-1)), is the key regulator of VEGF induced EC proliferation and migration 
(reviewed in Roskoski, 2008). VEGF binds with lower affinity to VEGFR2 compared 
to VEGFR1, but stimulates stronger tyrosine kinase activity of VEGFR2 than 
VEGFR1 (Waltenberger et al., 1994). In addition to VEGFR2 expression in ECs, 
VEGFR2 expression has been found also in neuronal cells, retinal progenitor cells, 
megakaryocytes and hematopoietic stem cells (Katoh et al., 1995). VEGFR2 is 
essential for early embryonic vasculogenesis and blood-island formation, Flk-1 
deficient mice die between E8.5-E9.5 because of abrogation of hematopoietic and EC 
differentiation (Shalaby et al., 1995). VEGF binding to the second and third Ig-like 
domains of VEGFR2 leads to receptor dimerization and strong phosphorylation of 
intracellular tyrosine residues (Fuh et al., 1998). VEGF-induced VEGFR2 
phosphorylation stimulates numerous downstream signalling pathways by 
phosphorylating phospholipase Cγ, ras GTPase activating protein, phosphoinositide 
3-kinase (PI3K) and Scr family kinases (Guo et al., 1995, Eliceiri et al., 1999). In 
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addition, VEGF stimulated VEGFR2 activation leads to activation of αvβ3-, αvβ5-, 
α5β1-, α2β1-integrins, which are dependent on PI3K - a serine/threonine kinase (Akt) 
signalling axis (Byzova et al., 2000). VEGFR2 activation induces also Raf-Mek-Erk 
signalling pathway via protein kinase C (PKC) resulting in EC proliferation 
(Takahashi et al., 1999). 
As mentioned above, VEGFR3 binds VEGF-C and VEGF-D ligands and it is a main 
regulator of lymphangiogenesis, and formation of lymphatic vasculature (Joukov et 
al., 1996, Achen et al., 1998, Tammela and Alitalo, 2010). VEGFR3 is expressed 
mainly in lymphatic ECs, but it is detected also in blood vascular ECs during 
embryonic development (Kaipainen et al., 1995). VEGFR3 can heterodimerize with 
VEGFR2 following VEGF-C stimulation inducing sprouting angiogenesis (Tammela 
et al., 2008, Nilsson et al., 2010). Although VEGFR3 is downregulated in adult blood 
vessels, it has been shown that VEGFR3 is upregulated in tumor angiogenesis (Valtola 
et al., 1999, Kubo et al., 2000). The activation of VEGFR3 induces downstream 
signalling pathways such as the PI3K-Akt pathway and phosphorylation of PKC-
mediated p42/p45 mitogen activated protein kinase (MAPK) (Makinen et al., 2001). 
 
Figure 1. Vascular endothelial growth 
factors and their receptors and co-receptors. 
VEGF, Vascular endothelial growth factor; 
VEGFR, Vascular endothelial growth 
factor receptor; NRP, Neuropilin; PlGF, 
placental growth factor. The image is 
modified from (Saharinen et al., 2011). 
  
 
 
1.2.2. Angiopoietin-Tie system 
Besides the VEGF-VEGFR system, angiopoietin growth factors together with their 
EC specific tyrosine kinase receptors Tie1 and Tie2 regulate vascular morphogenesis 
during embryonic development (Augustin et al., 2009, Eklund and Saharinen, 2013). 
In the mature adult vasculature, the Ang-Tie system contributes to inflammation, 
regulates endothelial barrier function and inflammatory vascular remodelling, and 
participates in pathological angiogenesis and lymphangiogenesis, for example in 
cancer (Augustin et al., 2009, Eklund and Saharinen, 2013) 
The Tie receptors are type 1 transmembrane protein RTKs (Ramsauer and D'Amore, 
2002), and they are expressed mainly in ECs (Dumont et al., 1994). Tie2 is also 
expressed in a muscle satellite cells (Abou-Khalil et al., 2009), in hematopoietic stem 
cells (Iwama et al., 1993, Ito et al., 2016) and Tie2 expressing 
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monocytes/macrophages (TEMs) (De Palma et al., 2003, De Palma et al., 2005). The 
ectodomain of these receptors consists of three fibronectin type III repeats (FN III), 
three epidermal growth factor (EGF)-like repeats and three Ig -like domains (Barton 
et al., 2006) (Figure 2.).  
 
Figure 2. The structure of the Tie receptors and a summary of Ang-Tie signalling. 
Ang1, Angiopoietin 1; Ang2, Angiopoietin 2; Ig, immunoglobulin like domain; EG, 
epidermal growth factor like repeat; FN III, fibronectin type III repeats; TK, tyrosine 
kinase; Akt, a serine/threonine kinase; Foxo1,  the Forkhead box protein O1; Rap1, 
Ras-proximate-1 or Ras-related protein 1; ROCK, Rho-associated protein kinase; 
α5β1, α5β1-integrin; P, phosphorylation.The image is modified from (Hakanpaa et al., 
2015). 
 
Angiopoietins bind to the Ig-EGF region of the Tie2 receptor (Fiedler et al., 2003, 
Barton et al., 2005), whereas no ligand has been identified for Tie1. Ligand binding to 
Tie2 leads to receptor complex formation with the Tie1 receptor (Saharinen et al., 
2005). The intracellular region of Tie2 is composed of a tyrosine kinase domain and 
C-terminal tyrosine phosphorylation sites, which are phosphorylated after ligand 
binding (Davis et al., 1996, Shewchuk et al., 2000). During embryonic development, 
Tie2 is necessary for cardiovascular development after mid gestation, and Tie2 deleted 
mouse embryos die between E10.5 to E12.5 due to the severe cardiac defects, lack of 
vascular remodelling and vessel maturation (Dumont et al., 1994, Sato et al., 1995).  
The function of the orphan Tie1 receptor is not fully understood. Tie1 expression is 
induced by VEGF and hypoxia in activated ECs (McCarthy et al., 1998). In addition, 
disturbed blood flow in branched blood vessels induces Tie1 expression (Porat et al., 
2004). Tie1 deficient mouse models have shown significant biological functions for 
Tie1. Tie1 null mouse embryos have impaired endothelial integrity and hemorrhages 
leading to lethality around E13.5 (Sato et al., 1995, Puri et al., 1995). In addition, 
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D’Amico et al. (2010) showed in another genetic background that Tie1 is also essential 
for lymphatic development; the Tie1−/− mouse embryos had malformed lymphatic 
vessels and edema, the embryos were swollen before signs of hemorrhage. Tie1 is also 
necessary for lymphatic valve formation and lymphatic remodelling and maturation 
(Shen et al., 2014, Qu et al., 2015). In addition, Woo and Baldvin (2011) consider that 
Tie1 could participate to atherosclerosis.  
The angiopoietin family consists of Ang1, Ang2 and Ang4 (the human orthologue of 
mouse Ang3) growth factors (also termed Angpt1, Angpt2 and Angpt4) (Davis et al., 
1996, Maisonpierre et al., 1997, Valenzuela et al., 1999, Lee et al., 2004). The 
angiopoietin structure consists of an N-terminal super-clustering domain (SCD) 
followed by a central coiled-coin domain (CCD), and C-terminal fibrinogen-like 
domain (Davis et al., 1996, Maisonpierre et al., 1997, Valenzuela et al., 1999). The 
CCDs of angiopoietins enable their homo-oligomerization, and the SCD further 
clusters angiopoietins into larger oligomers, including tetramers, and Ang1 in addition 
to larger multimers (Kim et al., 2005b). Angiopoietins bind Tie2 via their fibrinogen-
like domain (Procopio et al., 1999).  
Ang1 is a strong Tie2 agonist and it also activates Tie1 (Saharinen et al., 2005). Ang1 
stimulates the translocation of Tie receptors into EC-EC contacts resulting in EC 
stabilization (Fukuhara et al., 2008, Saharinen et al., 2008). In mice, Ang1 promotes 
structural integrity, survival and maturation of newly formed blood vessels, likely via 
its activity in EC-EC junctions (reviewed in Brindle et al., 2006). Tie2 promotes cell 
survival via activation of the PI3K-Akt serine kinase pathway resulting in activation 
of the endothelial nitric oxic synthetase (eNOS) (Kim et al., 2000). Activation of the 
Akt pathway results also to nuclear exclusion and inhibition of the Forkhead box 
protein O1 (Foxo1) transcription factor (Daly et al., 2004) (Figure 2.). Foxo1 
inhibition leads to downregulation of target genes involved in endothelial 
destabilization, metabolism, growth control and apoptosis (Brunet et al., 1999, Kim et 
al., 2000, Zhang et al., 2002, Wilhelm et al., 2016). Signalling in mobile EC is 
organized differentially: Tie2 is activated in EC-ECM adhesions via matrix-bound 
Ang1. Tie2 activation in mobile cell fosters activation of Erk and DokR, cell migration 
and matrix adhesion (Fukuhara et al., 2008, Saharinen et al., 2008).  
During early embryonic development (E9-E11), Ang1 is expressed in the embryonic 
heart myocardium surrounding the endocardium and it is essential for embryonic 
vascular development: Ang1 deficient mouse embryos die at the embryonic day E12.5. 
Even when the vasculature has developed, Ang1 deficient mice have less small vessels 
because of decreased branching (Suri et al., 1996). Instead, later during development 
Ang1 is expressed in mesenchymal cells surrounding the developing vessels (Davis et 
al., 1996). Ang1 forms tri-, tetra- and pentameric homo-oligomers that can further 
cluster into multimeric structures via its amino-terminal SCD. In order to activate Tie2 
in ECs, Ang1 must exist at least in a tetramer structure (Davis et al., 2003, Kim et al., 
2005b), although recently published data demonstrate that specifically designed 
recombinant dimeric Ang1 forms can activate Tie2 (Oh et al., 2015). Embryonic 
deletion of Tie2 results in lethality at around E10.5 with very similar embryonic 
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phenotype as observed in Ang1 null embryos (Dumont et al., 1994, Suri et al., 1996). 
However, Ang1 is dispensable in adult mice under baseline conditions, but required 
to attenuate aberrant pathological responses, such as in the diabetic kidney (Jeansson 
et al., 2011). 
Ang2 may act as a weak agonist or antagonist of Tie2 depending on the context 
(Maisonpierre et al., 1997). Ang2 is expressed by ECs where it is stored in special 
secretory granules, termed Weibel-Palade bodies (Fiedler et al., 2004). In adults, Ang2 
expression is low in the quiescent vasculature, but elevated in several diseases, such 
as sepsis (Parikh et al., 2006), atherosclerosis (Post et al., 2008), diabetes (Lim et al., 
2004) and in many cancers including breast cancer, melanoma, colorectal cancer, RCC 
and glioblastoma (Sfiligoi et al., 2003, Helfrich et al., 2009, Goede et al., 2010, Wang 
et al., 2014, Scholz et al., 2016). Upregulation of Ang2 expression in tumors promotes 
tumor growth, vascular de-stabilization and metastasis, which can be prevented using 
Ang2 blocking Abs (Holash et al., 1999, Holopainen et al., 2012, Leow et al., 2012). 
In addition, Ang2 expression increases in the tumor vasculature in response to hypoxia 
(Oh et al., 1999).  
During development, Ang2 agonist activity is required for the development of 
lymphatic vasculature (Gale et al., 2002), whereas Ang2 overexpression in transgenic 
mouse embryos leads to embryonic death during E9.5-E10.5 with vascular disorder, a 
similar phenotype that is detected in Ang1 or Tie2 deleted mouse embryos 
(Maisonpierre et al., 1997). Double deletion of Ang1 and Ang2 leads to development 
of glaucoma, and loss of function Tie2 mutations in humans cause primary congenital 
glaucoma (Thomson et al., 2014, Souma et al., 2016). In contrast, hyperactivated Tie2 
mutants result in venous malformations in human patients (Boscolo et al., 2015). 
1.2.3. Regulation of Ang-Tie signalling by Tie1 and integrins 
The Tie receptors undergo a unique cellular microenvironment-dependent mechanism 
of activation, stimulated by angiopoietins, leading to Tie receptor accumulation in the 
EC-EC junctions of endothelial monolayers. Instead, Tie receptors are accumulated 
on ECM contacts of the rear of the moving ECs (Fukuhara et al., 2008, Saharinen et 
al., 2008). 
Several studies show that the extracellular domain of Tie2 can undergo cleavage, 
which is induced by VEGF or phorbol myristate acetate (PMA) (Reusch et al., 2001, 
Findley et al., 2007, Onimaru et al., 2010). Soluble Tie2 (sTie2) has been detected in 
normal healthy human serum, and increased levels in coronary artery disease, 
congestive heart failure and RCC (Harris et al., 2001, Chung et al., 2003, Chong et al., 
2004). Also, cleavage of the extracellular domain of Tie1 by metalloprotease activity 
has been reported (McCarthy et al., 1999, Yabkowitz et al., 1999).  Soluble Tie1 
(sTie1) is detected in normal blood circulation, but sTie1 levels are elevated by PMA, 
VEGF, in inflammatory conditions by tumor necrosis factor-α (TNF-α) and shear 
stress in culture conditions (McCarthy et al., 1999, Yabkowitz et al., 1999, Chen-
Konak et al., 2003). Elevated levels of sTie1 are detected in lung, ovarian and breast 
cancer patients with thoracic or pelvic metastasis (Karnani and Kairemo, 2003). In 
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contrast to Tie2 ectodomain, Tie1 is unable to bind Ang1, and the cleaved sTie1 in 
circulation is not able to inhibit Ang1 induced Tie receptor signalling. Marron et al. 
(2007) demonstrated that cartilage oligomeric matrix protein (Comp) -Ang1 induced 
stronger Tie2 phosphorylation after Tie1 cleavage in ECs and suggested that the ability 
of Tie2 to bind ligand was increased after Tie1 cleavage. A similar effect was detected 
in Tie1 silenced cells. Instead, recently published data demonstrate that Tie1 cleavage 
in inflammation promotes the Tie2 antagonist activity of Ang2 suggesting that Tie1 is 
necessary for Ang-Tie signalling (Korhonen et al., 2016). 
Integrins regulate EC-ECM adhesion, and they also participate in angiogenesis 
(Hodivala-Dilke et al., 2003). Several studies have suggested that angiopoietins can 
interact with integrins (Cascone et al., 2005, Hakanpaa et al., 2015). Ang2 can bind to 
αvβ3-, αvβ5-, and α5β1-integrins, but interacts most strongly with α5β1-integrin (Felcht 
et al., 2012, Lee et al., 2014). Chen et al. (2009) demonstrated that Ang1 induced 
neurite growth occurred via the β1-integrin and activated focal adhesion kinase (FAK)-
PI3K-Akt pathway in Tie2 negative PC12 cell line. In addition, Lee et al. (2013) 
demonstrated that Ang1 induce EC migration and activate FAK via αvβ5-integrin in 
Tie2 negative retinal astrocytes. Carlson et al. (2001) compared the effect of Ang1 on 
cell adhesion and sprouting using ECs and Tie2 negative fibroblasts. Similar results 
were seen in these different cell lines suggesting that Ang1 induced cell adhesion and 
sprouting occur independently of Tie2. Interestingly, Ang1 mediated cell adhesion 
was inhibited with integrin blocking Abs (Carlson et al., 2001). Recently published 
data demonstrate that Ang2 activates β1-integrin leading to endothelial destabilization, 
but this effect was not seen with Ang1 (Hakanpaa et al., 2015). 
1.3. Formation of the blood vascular system 
1.3.1. Molecular regulation of angiogenesis 
The growth of new blood vessels is a highly controlled process regulated by 
angiogenic factors. The formation of blood vasculature can be classified into two main 
forms: vasculogenesis and angiogenesis. Vasculogenesis during early embryonic 
development is initiated by the formation of blood islands from the mesoderm layer 
of the yolk sac. The blood islands are clusters of hemangioblasts that differentiate to 
hematopoietic precursor cells and endothelial progenitor cells (reviewed in Ferguson 
et al., 2005). These EC progenitors then coalesce to form the primitive vascular plexus. 
Angiogenesis, the formation of the new blood vessels from pre-existing blood vessels, 
occurs during later stages of embryonic development and also throughout the 
adulthood (Ferguson et al., 2005). In adult organisms, physiological angiogenesis 
takes place for example during wound healing and tissue regeneration (Tonnesen et 
al., 2000), menstrual cycle (Augustin, 2005), and exercise-induced skeletal muscle 
growth (Prior et al., 2004). Angiogenesis is also a key process of many pathological 
conditions, including tumor angiogenesis promoting cancer progression, rheumatic 
disease and neovascular eye diseases, such as wet age-related macular degeneration 
(wAMD) (Risau, 1997, Ambati and Fowler, 2012). The formation of new blood 
vessels is regulated by two main RTK families: VEGFs and their receptors, and 
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angiopoietins and their Tie receptors in co-operation with other cellular pathways, 
including the Notch pathway (Jeltsch et al., 2013).  
1.3.2. Tip and stalk cells 
A highly investigated form of angiogenesis is sprouting angiogenesis, where 
specialized ECs are required to initiate and lead the growth of a new vessel branch. In 
the front line of sprouting vessels are specialized tip cells, which extend filopodia to 
probe and invade the microenvironment in response to VEGF gradient (Figure 3.) 
(Gerhardt et al., 2003). VEGF is secreted by hypoxic cells and is bound to the cell 
matrix, thereby providing guidance for tip cell migration. Behind the tip cells, stalk 
cells ensure the elongation of the stalk of the sprout by proliferation and forming the 
lumen (De Smet et al., 2009). Tip cells proliferate minimally whereas stalk cells 
proliferate forming EC-EC junctions to stabilize the nascent vessel (Carmeliet and 
Tessier-Lavigne, 2005). The most quiescent ECs are termed as phalanx cells, which 
are covered by perivascular cells, either pericytes or vascular SCMs, and tightly 
adherent to each other forming tight EC junctions regulating perfusion of newly 
formed blood vessels (De Smet et al., 2009). 
Figure 3. Receptors in sprouting angiogenesis. VEGFR2, VEGFR3, NRP-1, Dll4 and 
Tie1 receptors are expressed in tip cells. Tie2 is expressed in stalk cells. VEGF, 
Vascular endothelial growth factor; R2/3, Vascular endothelial growth factor receptor 
2/3; NRP-1, Neuropilin-1; PC, Pericyte; EC, Endothelial cell; Dll4, Delta-like ligand-
4; Notch, Notch receptor. The image is modified from (Jeltsch et al., 2013). 
Tip cells have specific molecular signalling components to regulate their specification 
as a tip cell. Tip cells express for example VEGFR2, VEGFR3, Delta-like ligand-4 
(Dll4) and NRP-1 and NRP-2 (Gerhardt et al., 2003, Gerhardt et al., 2004, Suchting 
et al., 2007, Tammela et al., 2008). NRPs are co-receptors for VEGFR2 and VEGFR3 
and NRP-1 is relevant for the function of tip cells (Favier et al., 2006, Pan et al., 2007). 
Also, Ang2 is highly expressed in tip cells (Felcht et al., 2012). 
In addition to vessel invasion to the surrounding tissue, the angiogenic process 
requires the degradation of ECM. ECM regulates the expression of matrix 
metalloproteinases (MMPs) that is expressed by tip cells to enhance the new forming 
vessel invasion (De Smet et al., 2009). Tip cells express membrane type-1 MMP 
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(MMP14), which plays a key role during angiogenesis and is downregulated in the 
stalk cells of stabilized vessels (Yana et al., 2007, van Hinsbergh and Koolwijk, 2008).  
VEGF binding to VEGFR2 induces several signalling pathways leading to EC 
specification as tip cells, including the formation of filopodia and highly polarized 
phenotype, and resulting in the initiation of migration towards the angiogenic stimulus 
(Gerhardt et al., 2003, De Smet et al., 2009). During this process, VEGF induced Dll4 
expression leads to activation of the Notch pathway in adjacent ECs resulting in the 
inhibition of VEGFR2 activity in the stalk cells (Roca and Adams, 2007). Tie2 is 
expressed in stalk and phalanx cells, but its expression is low in tip cells (del Toro et 
al., 2010). This may be due to Tie1 expression in tip cells resulting in inhibition of 
Tie2 presentation on the cell surface (Marron et al., 2007, Savant et al., 2015).   
Activation of the Notch signalling pathway in stalk cells leads to inhibition of vessel 
branching, decreasing filopodia expression and inhibition of the migratory response 
to VEGF via downregulation of VEGFR2 and VEGFR3 (Tammela et al., 2008, 
Williams et al., 2008, Jakobsson et al., 2009). For example in tumor models, inhibition 
of the Notch signalling pathway using anti-Dll4 Abs, or viral vectors encoding a 
soluble dimerized version of the extracellular region of Dll4 fused to the human IgG1 
Fc constant region, leads to stalk cell differentiation into tip cells, tip cell migration 
and vessel branching and increased vessel density, but interestingly, decreased tumor 
growth due to non-functional vasculature (Noguera-Troise et al., 2006, Ridgway et 
al., 2006). The postnatal retina is a highly used model to investigate sprouting 
angiogenesis, and many of the above mentioned results are observed in the retina 
(Gerhardt et al., 2003, Dorrell and Friedlander, 2006). Retinal vascular development 
is impaired in conditional deletions of Ang1, Ang2 and Tie1, indicating the 
requirement of the Ang-Tie pathway in physiological postnatal sprouting angiogenesis 
(Jeansson et al., 2011, Lee et al., 2013, D'Amico et al., 2010). 
1.4. Tumor angiogenesis and features of the tumor vasculature 
Nutrients and oxygen are essential for the growth and enlargement of tumors, and 
tumors also need to remove carbon dioxide and other metabolic wastes, similarly to 
normal tissues. All these functions require a functional blood circulation, created by 
tumor-associated neo-vascularization. In adult, the normal vasculature is quiescent for 
the majority of time, but during tumor progression “the angiogenic switch” will turn 
a program that results in new vessel growth from nearby vessels. This switch occurs, 
via activation of a variety signalling mechanisms, most importantly VEGF and 
angiopoietin signalling pathways (Hanahan and Weinberg, 2011). Similar to the 
normal vasculature, the tumor vasculature consists of ECs, mural cells (pericytes or 
vascular SMCs) and the BM, but all of these constituents are abnormal and their 
functions altered from the normal vasculature. One example is the altered VEGF 
dependence of the tumor endothelium, sustaining angiogenesis even in the presence 
of VEGF blocking therapy and creating a challenge for development of effective anti-
angiogenic cancer therapies (Baluk et al., 2005). In contrast to the vasculature in 
healthy tissues, proangiogenic signals induced in the tumor stimulate functional and 
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structural abnormalities in tumor vessels; the blood flow is erratic, proliferation and 
apoptosis of ECs is abnormal creating a poorly organized vascular network, vessels 
undergo sprouting, remodelling, and proliferation in response to constant VEGF 
signalling, and vessel enlargement and branching occurs (Baluk et al., 2005, Nagy et 
al., 2010). In contrast to healthy vasculature, tumor vasculature does not contain a 
normal tight EC layer and tight EC-EC junctions, which leads to vessel leakiness 
contributing to tumor metastasis. Some tumors are especially bloody with large “blood 
lakes”, and tumor hemorrhage is an indication of abnormal and leaky vasculature with 
a defective endothelial barrier function (Hashizume et al., 2000). In addition to high 
VEGF expression, which stimulates vessel leakiness, another reason for leaky tumor 
blood vessels can be the decreased attachment of pericytes to ECs (Abramsson et al., 
2002, Morikawa et al., 2002). Several studies have shown that alterations on plateled-
derived growth factor (PDGF) signalling affect the association of pericytes to tumor 
vessels (Abramsson et al., 2002, Abramsson et al., 2003, Furuhashi et al., 2004). In 
addition, Holash et al. (1999) describe that in a rat glioma model, pericyte detachment 
and regression was associated with Ang2 expression in ECs leading to tumor hypoxia, 
upregulation of VEGF expression and tumor angiogenesis. 
Vascular BM with MMPs and vascular integrins regulate tumor angiogenesis. Also, 
the tumor vascular BM differs from normal tissues. The vascular BM of normal tissue 
vasculature consists of type III, IV and VII collagen, laminin, nidogens, and 
proteoglycans forming a tight envelope between the ECs and pericytes (reviewed in 
Kalluri, 2003). Instead, in tumors, BM is not associated with ECs and consists of focal 
holes, and has an altered composition including for example upregulated expression 
of fibronectin and its receptor α5β1-integrin (reviewed in Baluk et al., 2005). 
1.4.1. VEGFs and Ang2 in tumor angiogenesis 
The VEGF-VEGR2 signalling axis is the major regulator of tumor angiogenesis, and 
many tumors including neoplastic tumor and stromal cells, secrete VEGF (Ferrara, 
2004, Ferrara and Adamis, 2016). RCC is an example of a tumor, which expresses 
VEGF mRNA at a very high level (Tomisawa et al., 1999, reviewed in Ferrara et al., 
2007). VEGF is also detected by immunohistochemical (IHC) staining in breast 
(Yoshiji et al., 1996) and kidney cancer (Nicol et al., 1997), and elevated serum VEGF 
levels are detected in ovarian cancer (Yamamoto et al., 1997). VEGF mRNA is 
elevated also in pituitary adenomas (Lloyd et al., 1999) and thyroid cancer (Soh et al., 
1997). VEGF is upregulated by hypoxia and it is a target gene of the HIF transcription 
factor. HIF stability is regulated by von Hippel-Lindau (VHL) tumor suppressor that 
in normoxic conditions targets HIF to degradation (Safran and Kaelin, 2003).  
The importance of VEGF to tumor angiogenesis and tumor growth was originally 
shown by Kim et al. (1993), who demonstrated in pioneering studies that a monoclonal 
Ab against VEGF decreased the growth of tumors, and the density of tumor vessels in 
mice. Subsequently, tumor growth inhibition was demonstrated in many other studies 
using various VEGF blocking agents. Millauer et al. (1994) showed that the growth 
of human glioblastoma tumor xenografts was inhibited in nude mice expressing 
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a dominant-negative mutant of the Flk-1/VEGF receptor via viral vector delivery. 
Also, adenoviral mediated gene transfer of soluble VEGF receptor (or a fusion of the 
first three Ig domains of VEGFR1 and the constant region of human IgG1) inhibited 
tumor growth in immunodeficient mouse tumor models (Goldman et al., 1998, Kong 
et al., 1998, Holash et al., 2002). Prewett et al. (1999) demonstrated that Ab against 
VEGF receptor flk-1 (VEGFR2) decreased MVD and tumor cell proliferation, and 
tumor necrosis was extensive in experimental mouse tumors. Willet et al. (2004) first 
demonstrated that blocking VEGF has clinical benefit in human patients, by showing 
that blocking human VEGF with a humanized monoclonal Ab (bevacizumab) in 
cancer patients decreases tumor vascular volume and microvascular density, tumor 
perfusion and interstitial fluid pressure. The humanized anti-VEGF Ab bevacizumab 
inhibits VEGF-VEGFR2 interaction, and was the first anti-angiogenic therapy 
accepted in clinical use, for the treatment of metastatic colorectal cancer (Ferrara and 
Kerbel, 2005, Strickler and Hurwitz, 2012). Since then, additional VEGF-VEGFR2 
targeted therapies have been developed and approved for use in a wide variety of 
human cancers. Despite of clear tumor control benefit in certain cancers, not all tumors 
are sensitive to VEGF-targeted therapies and those that initially respond, often become 
resistant to the treatment (Abdullah and Perez-Soler, 2012, Sennino and McDonald, 
2012, Singh and Ferrara, 2012). One potential explanation for therapy associated 
resistance is that tumors may be able to switch and use another receptor-ligand 
pathway instead of the VEGF pathway and this way maintain vessel sprouting and 
tumor angiogenesis in the presence of VEGF inhibitors. For example, the tumor 
vasculature expresses also VEGFR3 which can be activated by VEGF-C and VEGF-
D, produced by tumor and inflammatory cells, or in addition, the proteolytically 
processed forms of VEGF-C and VEGF-D can activate VEGFR2 directly (Joukov et 
al., 1997, Stacker et al., 2001, Karpanen and Alitalo, 2008).  
Besides the VEGF family and their receptors, also the Ang-Tie system is involved in 
tumor angiogenesis. High circulating Ang2 levels and increased mRNA expression 
have been found to predict for poor prognosis in melanoma (Helfrich et al., 2009), 
metastatic colorectal cancer (Goede et al., 2010), glioblastoma (Scholz et al., 2016) 
and in breast cancer (Sfiligoi et al., 2003). ECs of RCC and human glioblastoma have 
been reported to express Ang2 (Rautiola et al., 2016, Scholz et al., 2016). 
Blocking Ang2 in mouse tumors reduces tumor angiogenesis by reducing the number 
of angiogenic sprouts, and the combination of Ang2 and VEGF blocking inhibitors 
shows increased efficacy when compared to either monotherapy (Brown et al., 2010). 
Oliner et al. (2004) showed that using anti-Ang2 Abs and peptide-Fc fusion proteins 
that prevent the interaction of Ang2 and Tie2 receptor resulted in reduced EC 
proliferation and inhibition of tumor growth in human epidermoid and colorectal 
tumor xenografts. Importantly, we showed that blocking Ang2 inhibits significantly 
tumor growth by reducing the number of tumor blood vessels in lung cancer 
xenografts. Blocking Ang2 also reduced the number of lymphatic vessels and lymph 
node metastasis, as well as metastasis to lungs by improving EC junctions of 
metastasis associated capillaries (Holopainen et al., 2012). Interestingly, several 
studies show that anti-Ang2 treatment combined to VEGF blocking inhibited tumor 
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growth in mouse models (Hashizume et al., 2010, Daly et al., 2013, Kienast et al., 
2013). Falcón et al. (2009) demonstrated that a peptibody Ang2 inhibitor (L1-7[N]) 
reduced tumor growth and decreased the number of blood vessels in human colon 
xenografts. Ang2 blocking treatment resulted in tumor vascular normalization 
including accumulation of vascular endothelial cadherin (VE-cadherin) to the EC-EC 
junctions; increased pericyte coverage around the vessels and reduced endothelial 
sprouting. Pericytes are an important element to stabilize tumor vessels. Keskin et al. 
(2015) showed that targeting pericytes resulted in elevated Ang2 levels in a human 
mammary tumor xenograft mouse model leading to leaky vessels and increased lung 
metastasis, but the combination with blocking Ang2 treatment restored vascular 
stabilization, decreased metastasis and supressed tumor growth. 
Ang1 overexpression in human xenograft models results in pericyte covering of the 
blood vessels (Hawighorst et al., 2002). Interestingly, mixed effects on tumor growth 
have been demonstrated by endogenous or exogenous viral vector-mediated Ang1 
overexpressing in certain tumor models. Ang1 has been shown to inhibit tumor growth 
in several studies (Hayes et al., 2000, Hawighorst et al., 2002, Stoeltzing et al., 2003), 
but tumor growth promoting effects have been also indicated (Machein et al., 2004). 
Recombinant Ang1 has been demonstrated to stimulate EC proliferation resulting in 
vascular enlargement in mouse post-natal retina and postcapillary venules indicating 
that Ang1 participates and stimulates vessel remodelling in normal tissue (Thurston et 
al., 2005, Lee et al., 2013). In tumors, blocking Ang1 had almost no effect on the 
vasculature, instead, together with an Ang2 inhibitor, Ang1 inhibitor prevented tumor 
vessel normalization indicating that Ang1 has a stabilizing effect on the vasculature 
(Falcon et al., 2009). 
Tie1 expression is increased in human and mouse tumor vessel, and Tie1 deletion in 
the endothelium of adult mice resulted in inhibition of tumor growth and angiogenesis 
(Kaipainen et al., 1994, D'Amico et al., 2014). Tumors grown in Tie1 deficient mice 
had less tumor blood vessels and less tumor cell proliferation when compared to 
control, wild type (WT) mice (D'Amico et al., 2014). Tie1 deletion also increased 
apoptosis in ECs and tumor cells, and decreased vessel sprouts. 
1.5. Regulation of vascular permeability 
1.5.1. Endothelial cell-cell junctions 
Cellular junctions are important for EC communication and adhesion to the 
surrounding cells and tissues. The junctional EC transmembrane proteins are anchored 
to the actin cytoskeleton via specific intracellular proteins to stabilize the junctions 
and transfer the intracellular signals (reviewed in Bazzoni and Dejana, 2004). Also, 
the dynamic regulation of junction opening and closing is provided by transmembrane 
receptor adhesion to the cytoskeleton (Hartsock and Nelson, 2008). The EC junctions 
have been categorized as adherent, tight and gap junctions and are formed according 
to vessel type and permeability requirements of the target organ. Whereas the gap 
junctions provide the communication between the neighbouring cells, tight junctions 
enable the “barrier” by regulating the vessel permeability, and they also sustain cell 
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polarity. Maturation and maintenance of EC-EC contacts are provided by adherent 
junctions (Bazzoni and Dejana, 2004, Dejana et al., 2009). Both, the adherent and the 
tight junctions participate in the transfer of the intracellular signals that control many 
EC functions (Dejana et al., 2009). In general, junctions are functional structures that 
change according to their environment, and also intracellular adhesive proteins that 
are attached to the transmembrane proteins vary during the junction maturation and 
stabilization (Ayalon et al., 1994, reviewed in Bazzoni and Dejana, 2004) (Figure 4.). 
 
Figure 4. Tight and adherent junctions in endothelial cells. ZO-1-3, Zonula occludens 
1-3; JAM, junction adhesion molecule; Ang1, Angiopoietin-1; VEGFR, Vascular 
endothelial growth factor receptor; NRP, Neuropilin; α/β/γ/p120, Catenins. The image 
is modified from (Dejana, 2004). 
 
Cell adhesion at adherent junctions is mediated by proteins of the cadherin family, 
including N-cadherin and VE-cadherin that are expressed in all vessel types. Both 
cadherins bind by their cytoplasmic C-terminal domains to catenins, such as β-catenin, 
p120 and plakoglobin. β-catenin and plakoglobin bind to the actin binding protein α-
catenin (Vestweber, 2008). α-catenin binds to the actin-binding proteins vinculin 
(Weiss et al., 1998), α-actinin (Knudsen et al., 1995) and zonula occludens-1 (ZO-1), 
which is mainly present at tight junctions (Itoh et al., 1997). This catenin-actin 
dependent mechanism has been identified to strengthen the EC junctions, but 
interestingly, Yamada et al. (2005) challenged this theory by showing that actin was 
unable to bind to the E-cadherin-β-catenin-α-catenin complex. Still, catenin 
deficiency destabilized the cadherin mediated cell adhesion (Vestweber, 2008).  
VE-cadherin is essential for regulating vascular permeability and integrity. Corada et 
al. (1999) demonstrated that administration of the anti-VE-cadherin Abs increased 
vascular permeability, fragility and hemorrhages in vivo. The same report 
demonstrated in cultured cells, that the Ab blocking of VE-cadherin induced 
redistribution of VE-cadherin, but it did not affect the tight junction marker ZO-1. 
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VEGFR2 has been shown to associate with VE-cadherin and this association is rapidly 
dissociated after VEGF stimulation (Weis et al., 2004). In addition to stimulation of 
angiogenesis, VEGF is also a powerful factor inducing vessel leakiness. VEGF 
activation of VEGFR2 signalling induces the tyrosine phosphorylation of VE-
cadherin, β-catenin, γ-catenin/plakoglobin and p120-catenin resulting in dismantling 
of EC-EC contacts (Esser et al., 1998). Additional mechanisms have been reported 
that contribute to VEGF-induced vascular leakiness. Wu et al. (2003) showed that 
inhibition of FAK that is induced by VEGF and participate in EC adhesion and 
migration, significantly decreased VEGF elicited vascular hyperpermeability in vivo. 
Wu et al. (1999) showed that inhibition of eNOS, PLC- , or PKC blocked VEGF 
induced vascular permeability in vivo. Phosphorylation of VE-cadherin may be also 
due to inhibition of associated phosphatases, including the receptor-type tyrosine-
protein phosphatase beta (VE-PTP), which is reported to associate with VE-cadherin 
(Nawroth et al., 2002) and Tie2 (Fachinger et al., 1999). Baumer et al. (2006) 
demonstrated that homozygous VE-PTP mutant mouse embryos lacking the VE-PTP 
phosphatase domain, died at E10 without hierarchically organized vascular network 
and defects on heart development, and the growth of embryos between E8.5-E9.5 was 
significantly retarded. These results are in line with VE-cadherin deficient mice 
(Carmeliet et al., 1999) suggesting that vessel development is retarded in situation 
where VE-cadherin is constitutively phosphorylated. In addition, it has been reported 
that cleavage of VE-cadherin by metalloproteases can also promote vascular 
permeability (Herren et al., 1998).  
As described above, VE-PTP has been reported to associate with Tie2, resulting in 
dephosphorylation of Tie2 (Fachinger et al., 1999). Treatment of ECs with a function 
blocking anti-VE-PTP Ab resulted in Tie2 phosphorylation and downstream 
activation of Erk1/2, which induced EC proliferation and vascular enlargement 
(Winderlich et al., 2009). Interestingly, in a recent study, Frye et al. (2015) 
demonstrated, that VE-PTP inhibition stabilized EC junctions via Tie2 in vivo. 
Blocking VE-PTP with a specific pharmacological small molecule inhibitor (AKB-
9778) inhibited vascular leakiness induced by inflammatory mediators, and decreased 
leukocyte transmigration through the endothelial barrier. This was mediated by Tie2 
induced Ras-proximate-1 (Rap1)-Rac1 signalling pathway resulting in the 
stabilization of cortical actin in ECs. Instead, in the absence of Tie2, VE-PTP blocking 
Ab destabilized endothelial junctions, which did not occur in the absence of VE-
cadherin (Frye et al., 2015). Ang1 stimulation induces VE-PTP accumulation in EC-
EC junction (Saharinen et al., 2008), where it also associates with Tie2, and 
dephosphorylates VEGFR2 (Mellberg et al., 2009). Thus, VE-PTP accumulation in 
EC-EC junctions in response to Ang1, may downregulate VEGFR2 signalling 
pathway promoting the barrier function (Mellberg et al., 2009). 
Various growth factors, such as VEGF, as well as inflammatory mediator histamine 
and thrombin, and cytokines promote vascular leakiness, which can be inhibited by 
Ang1 (Thurston et al., 2000, Baffert et al., 2006). Several in vitro studies in ECs 
suggest that Ang1 can stabilize EC-EC junctions, decreasing EC monolayer 
permeability and modulating the activation of junctional molecules (Gamble et al., 
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2000, Wang et al., 2004). Ang1 has been reported to promote the accumulation of the 
platelet endothelial cell adhesion molecule-1 (PECAM-1) to EC junctions and 
decrease the phosphorylation of VE-cadherin and PECAM-1 (Gamble et al., 2000). In 
contrast, Ang2 in concert with inflammatory cytokines has been reported to induce 
vascular leakiness (Benest et al., 2013). 
Tight junctions are composed of transmembrane proteins such as occludins, claudins, 
junction adhesion molecules (JAMs), and intracellular proteins of the ZO family 
(reviewed in Bazzoni and Dejana, 2004). Occludin binds ZO-1 (Furuse et al., 1994), 
ZO-2 (Itoh et al., 1999b) and ZO-3 (Haskins et al., 1998). EC-EC adhesion in tight 
junctions is mediated mainly via the claudin family containing more than 20 members, 
of which only few, such as claudin-1, -3 and -5, are expressed in ECs (reviewed in 
Dejana et al., 2009). All claudins from claudin-1 to claudin-8 bind ZO proteins 1-3 
(Itoh et al., 1999a). ZO family members are reported to bind to each other and 
associate with the cortical actin cytoskeleton, co-precipitating with F-actin. ZO-1 (Itoh 
et al., 1997) and ZO-2 (Itoh et al., 1999b) bind α-catenin (reviewed in Bazzoni and 
Dejana, 2004). Also, JAM family members and endothelial cell-selective adhesion 
molecule (ESAM) transmembrane glycoproteins are expressed in the tight junctions 
(reviewed in Dejana et al., 2009).  
1.5.2. Inflammation 
Vascular permeability and leukocyte transmigration are increased in inflammation. 
This phenomenon is associated with VE-PTP dissociation from VE-cadherin leading 
to phosphorylation of cytoplasmic residues of VE-cadherin resulting in leaky vessels 
(Broermann et al., 2011, Vockel and Vestweber, 2013, Wessel et al., 2014). VE-PTP 
is a target gene of HIF-2α, which is highly expressed in ECs and induced by hypoxia 
(Gong et al., 2015). Gong et al. (2015) demonstrated that HIF prolyl 4-hydroxylase 2 
(PHD2) inhibitor stabilizes HIF-2α resulting in increased VE-PTP expression and 
dephosphorylation of VE-cadherin, which promoted the integrity of adherent 
junctions and endothelial barrier function in a lipopolysaccharide (LPS) induced 
inflammation model. In addition, VE-cadherin internalization is increased by 
inflammatory mediators (Gong et al., 2014), and VE-cadherin endocytosis leads to 
disassembly of adherent junctions and increases vascular permeability (Gavard and 
Gutkind, 2006, Gong et al., 2014).   
As described above, Ang1 can inhibit vascular permeability via Tie2 (Thurston et al., 
2000), whereas Ang2 has been described to be critical for cytokine-induced vascular 
leakage (Benest et al., 2013).  Fuxe et al. (2011) demonstrated that vascular leakiness 
was prevented with Comp-Ang1 in Mycoplasma Pulmonis infected mice, and this 
required PDGF-dependent recruitment of pericytes. Basal and LPS-induced vascular 
permeability was increased after Tie2 silencing in vivo using siRNA in Tie2 deficient 
mice, and reduced Tie receptor expression in mice predisposed to hemorrhagic 
complications of murine ebola hemorrhage fever, resulting resistance to a vascular 
leakiness indicating the importance of Tie2 for vascular barrier function (Rasmussen 
et al., 2014, Frye et al., 2015).  
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Increased Ang2 levels have been reported in sepsis (Parikh et al., 2006), which may 
due to decreased signalling via the Ang-Tie-Akt pathway resulting in Foxo-1 nuclear 
translocation and stimulation of Ang2 expression (Daly et al., 2006, Ghosh et al., 
2015). For example, Ang2 was elevated and Tie2 phosphorylation was decreased in 
mucosal blood vessels in mice airways infected by Mycoplasma Pulmonis (Tabruyn 
et al., 2010). In this study, reduced Tie2 phosphorylation was supressed and 
remodelling of mucosal capillaries into venules was decreased when Ang2 blocking 
Abs were used to treat the mice (Tabruyn et al., 2010). In addition, the amount of 
leukocyte influx was decreased. Le et al. (2015) demonstrated that Ang2 blocking Abs 
inhibited vascular leakage and vessel enlargement synergistically, with TNF-α 
blocking Abs. TNF-α is an inflammatory cytokine upregulated in inflammation and 
sepsis (Tisoncik et al., 2012).  Fiedler et al. (2006) showed in Ang2 deficient mice that 
TNF-α induced leukocyte rolling on the luminal EC surface of the blood vessels but 
that leukocytes did not adhere to the activated endothelium. In addition, the same study 
showed that Ang2 sensitized ECs for TNF-α mediated upregulation of intercellular 
adhesion protein (ICAM-1). Interestingly, Han et al. (2016) showed recently that a 
novel Ang2 Ab ABTAA, that mediates clustering of ABTAA/Ang2-Tie2 complexes 
induced Tie2 phosphorylation. This Ab was more effective in vascular protection in 
sepsis compared to a conventional Ang2 blocking Ab, which inhibits Ang2 binding to 
Tie2. 
It has been shown that Ang2 also binds to and signals via β1-integrin (Felcht et al., 
2012, Hakanpaa et al., 2015). Ang2 binding to β1-integrin leads to actin stress fiber 
formation and changes in EC-ECM adhesion resulting in destabilization of the EC 
monolayer (Hakanpaa et al., 2015). Felcht et al. (2012) showed that Ang2 bound to 
abundantly expressed integrins in Tie2 deficient, angiogenically active ECs, resulting 
in phosphorylation of FAK and RAC-1 and leading to EC migration and sprouting 
angiogenesis. In addition, α5β1-integrin has been demonstrated to co-
immunoprecipitate (co-IP) with Ang2 in TNF-α stimulated ECs (Felcht et al., 2012). 
Tie2 expression has been described to decline in infections associated to leaky vessels, 
such as in sepsis, malaria, influenza and anthrax (reviewed in Ghosh et al., 2016). 
2. Renal cell carcinoma (RCC) 
2.1. Epidemiology and pathology 
RCC is a highly vascular tumor, which accounts for approximately 2-3 % of all adult 
malignancies. It is male dominant, and has an increasing rate of incidence in many 
countries (Hollingsworth et al., 2006, Rini et al., 2009). Obesity (Bjorge et al., 2004, 
van Dijk et al., 2004), active and passive smoking (Hunt et al., 2005) and end-stage 
renal failure and renal cystic disease are established risk factors for RCC (Ishikawa et 
al., 2003, Rakowski et al., 2006).  
RCC is not a one entity but rather a collection of different types of tumors containing 
specific attributes, such as histological features, clinical phenotypes and possessing 
distinct genetic characteristics (Zambrano et al., 1999, Renshaw, 2002, Linehan et al., 
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2003, Rini et al., 2009). RCC can be classified in several histological subtypes with 
different prevalence: clear cell 80%, papillary 10%, chromofobe 5% and medullary 
and collecting tube <1% (Ngo et al., 2014). Clear cell RCC (ccRCC) and papillary 
RCC (pRCC) are thought to arise from the proximal tubular epithelial cells, whereas 
collecting duct carcinoma appears from the ducts of Bellini and chromophobe RCC 
from the distal nephron (Verdorfer et al., 1998, Rini et al., 2009). 
The most common subtype of RCC is ccRCC and it is named because of the high 
content of the cytoplasmic lipids dissolving during the histological preparation and 
resulting in a clear cytoplasm (Rini et al., 2009). VHL disease is related to the sporadic 
and hereditary forms of ccRCC (Renshaw, 2002). The second common subtype of 
RCC is pRCC and it is further divided into type 1 and a more aggressive type 2 pRCCs 
(Rini et al., 2009). No differences in the 5-year cancer-specific survival has been 
observed between patients with pRCC and ccRCC (Waldert et al., 2008).  
2.2. von Hippel-Lindau (VHL) and hypoxia 
VHL is a tumor suppressor gene located in chromosome 3 (3p25-26). VHL mutations 
are responsible for the most common hereditary syndrome in RCC (Rini et al., 2009). 
Usually the loss of the second allele, mutation or inactivation of the promoter region 
of VHL gene leads to VHL syndrome (Pavlovich et al., 2003). Patients diagnosed with 
VHL disease usually develop pre-neoplastic renal cysts that can lead to clear-cell type 
carcinoma (Kaelin, 2002). Besides RCC, VHL mutations appear also in highly 
vascularized haemangioblastoma of the central nervous system and 
pheochromocytomas (Rini et al., 2009). VHL regulates HIF-1α and HIF-2α, and in 
normal physiologic conditions and normal oxygen level, VHL protein (pVHL) binds 
to prolyl-hydroxylated HIF-αs, resulting its ubiquitination and degradation by the 
proteasome (Bader and Hsu, 2012). In hypoxic conditions HIF-α translocates to the 
nucleus, dimerizes with HIF-1β, and acts as a transcription factor inducing gene 
expression of several genes involved in angiogenesis (VEGF and PDGF), 
erythropoiesis, glucose uptake and metabolism and transforming growth factor-α 
(TGFα) (Kaelin, 2002, Kaelin, 2007). When VHL gene is mutated, it does not bind 
hydroxylated HIF-α, which results in nuclear localization of HIF-α, formation of the 
αβ-dimer and activation of HIF-target genes (Bader and Hsu, 2012).  
2.3. Metastatic renal cell carcinoma (mRCC) 
In 25-30% of RCC patients, the tumor has metastasized by the time they are diagnosed 
(Motzer et al., 1996), and 20-40% patients undergoing nephrectomy of the primary 
tumor will develop metastasis (reviewed in Lam et al., 2005). Usually RCC metastasis 
are found in the lung parenchyma (50-60%), bone (30-40%), liver (30-40%) and brain 
(5%) (Motzer et al., 1996). mRCC is highly resistant to chemotherapy and in the 
majority of the cases to cytokine-based immunotherapy, bur responds to immune 
check-point inhibitors (Rini et al., 2009, Coppin et al., 2011). Even though seven 
targeted therapies for mRCC have been approved since 2005, including inhibitors of 
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VEGF and the mammalian target of rapamycin (mTOR), the prognosis of mRCC is 
poor and complete durable responses are rare (Escudier et al., 2014b).  
2.4. Microvessel density 
MVD is the most frequently used parameter to quantify intratumoral angiogenesis 
(Cheng et al., 2014).  Many studies show that tumors with a high MVD are more 
aggressive and predispose to tumor metastasis (reviewed in Baluk et al., 2005). It has 
been shown that CD31 expression correlates significantly with poor prognosis and 
metastasis in ccRCC patients (Joo et al., 2004). Instead, in patients treated with 
antiangiogenic therapy, Dornbusch et al. (2013) showed that high CD31 expression 
compared to low CD31 in primary tumors of mRCC patients treated with sunitinib 
showed better response to treatment. Sharpe et al. (2013) demonstrated that mRCC 
patients with higher levels of CD31 and Ki-67 were associated with delayed 
progression. They also showed that tumor vessel density (CD31) was significantly 
decreased after TKI (sunitinib and pazopanib) treatment in patients treated before 
nephrectomy, and during the therapy increased CD31 correlated with reduced OS. del 
Puerto-Nevado et al. (2014) demonstrated that active angiogenesis in RCC patients 
predicted the benefit to first-line sunitinib. They showed that phosphorylated VEGFR2 
in the tumor stroma was associated with significantly prolonged PFS and OS when 
treated with sunitinib, but MVD did not show statistical difference in terms of PFS 
and OS. 
2.5. Therapeutic options 
In localized RCC, the treatment involves partial or radical nephrectomy, and the 
choice of treatment needs to be individualised (Van Poppel et al., 2011). The 
treatments of mRCC consist of targeted therapies and surgery, most often the 
combination of both treatments, but usually patients with recurrent mRCC or whom 
surgery is not advisable, the systemic treatment is recommended (Rini et al., 2009).   
2.5.1. Immunotherapy 
The standard care for mRCC was immunotherapy for many years, specifically 
interleukin-2 (IL-2) and interferon-α, even though the effectiveness of these 
treatments is disputable (Rini et al., 2009). Also, the adverse effects of IL-2, including 
capillary leak syndrome, tachycardia, hypertension, dyspnea and pulmonary 
congestion, gastrointestinal and renal toxicities, limited the use of this therapy (Poust 
et al., 2013). IL-2 was approved by Food and Drug Administration (FDA) in the US 
because of its effect in high dose treated mRCC patients: durable complete remission 
occurred in 7-8% of patients (Fyfe et al., 1995, Fisher et al., 2000, reviewed in Rini et 
al., 2009). Combination of low-dose IL-2 and interferon treatment provided prolonged 
response rate and PFS compared to either drug alone but it did not affect to OS 
(Negrier et al., 1998). It has been showed that high level of carbonic anhydrase-9 
(CAIX), a VHL mediated protein and a target of hypoxic VHL signalling pathway, is 
associated with poor prognosis in RCC (Bui et al., 2003). In addition, it has been 
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demonstrated that CAIX might be a predictive biomarker to high dose IL-2 treatment 
and patients with high level of CAIX might benefit the treatment (Atkins et al., 2005). 
Dudek et al (2010) showed that mRCC patients without tumor CAIX expression 
detected by IHC did not response to IL-2 therapy. Instead, recently published results 
show that durable and objective response to IL-2 therapy did not associate with high 
tumoral CAIX expression (McDermott et al., 2015).  
Interferon-α has provided survival combined with medroxyprogesterone acetate and 
vinblastine when compared to treatments alone (Pyrhonen et al., 1999, Medical 
research council renal cancer collaborators, 1999). Instead, no benefit on PFS or OS 
was registered in interferon-α or IL-2 treated mRCC patients compared to 
medroxyprogesterone, and toxicity grade was significantly higher in cytokine-treated 
patients compared to medroxyprogesterone-treated ones (Negrier et al., 2007). More 
investigation is needed to select the patients who benefit from treatment, and in 
addition, more identification of clinical and biological predictors to response cytokines 
are needed. Interestingly, in randomized, double blind phase III trial, interferon-α 
combined with targeted therapies in mRCC patients showed a significant 
improvement in PFS when compared to interferon-α treatment alone (Escudier et al., 
2007b).  
2.5.2. Tyrosine kinase inhibitors (TKIs) 
An increased understanding of tumor biology and molecular signalling pathways has 
established the development of targeted therapies in RCC. For example, the 
differences in protein levels in RCC caused by VHL gene mutations resulted in the 
understanding of the function of VEGF and mTOR as relevant targets in RCC 
(reviewed in Rini et al., 2009). Drugs that target these pathways have been developed 
against the VEGF ligand or VEGFRs, and seven of these targeted drugs have been 
approved by European Medicines Agency (EMA) and the FDA for the use of mRCC 
(Escudier et al., 2014b). 
Sunitinib is a multi-targeted TKI, which FDA authorized for treatment of mRCC on 
January 26, 2006. It is now widely used as a first-line therapy for mRCC. Sunitinib is 
an oral drug that inhibits VEGFRs, PDGFRa/b, KIT, Flt-3 and CSF-1 (Powles et al., 
2011). Previous studies have shown ORRs of 25-47% to sunitinib in mRCC, however 
complete durable responses are rare (Motzer et al., 2006). In addition, approximately 
11 months after the initiation of sunitinib treatment disease progression usually occurs 
(Motzer et al., 2009b). In phase III clinical trials, sunitinib treatment compared to 
interferon-α increased median PFS of RCC patients, 11 months vs. 5 months, 
respectively (Motzer et al., 2007). In the same study, median OS was greater in 
sunitinib treated (26.4 months) than interferon-α group (21.8 months) (Table 1.) 
(Motzer et al., 2009b). Also, the quality of life was better in sunitinib treated patients 
(Motzer et al., 2007), even though adverse effects such as hypertension (12%), fatigue 
(11%), diarrhea (9%), and hand-foot syndrome (9%) were reported in the sunitinib 
arm (Motzer et al., 2009b). In addition, not all patients benefited from the sunitinib 
treatment (Motzer et al., 2009b, Busch et al., 2011). To improve efficacy, 
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investigational Ang1/Ang2 blocking peptibody trebananib, which inhibits the 
interaction of angiopoietin and Tie2, has been combined with sunitinib in clinical 
phase II RCC trials (Atkins et al., 2015). In this study, the dose effect of trebananib 
(low dose: group A, high dose: group B) to survival of mRCC patients was 
investigated. Trebananib treatment was combined with sunitinib. The ORR was 58% 
in group A, and 63% in group B. PFS was prolonged in group B, when compared to 
group A (16.3 months vs. 13.9 months, respectively). Although the efficacy results 
show a benefit for the higher dose of trebananib, the combination therapy with both 
doses (high and low doses of trebananib) increased the drug toxicity: more than half 
of patients in both group (high and low doses of trebananib) had sunitinib interruption, 
and most common adverse events were diarrhea, mucosal inflammation and 
hypertension (Atkins et al., 2015).  
Pazopanib is an oral angiogenesis inhibitor that blocks VEGFRs, PDGFRs and c-Kit 
(Sternberg et al., 2010). In a randomized, double blind, placebo controlled clinical 
phase III trial patzopanib showed similar efficacy than sunitinib (Sternberg et al., 
2010). In this study RCC patients, including treatment-naïve or previously treated with 
pazopanib, were randomized to receive placebo or pazopanib. Overall population PFS 
was 9.2 months vs. 4.2 months in pazopanib treated vs. placebo, respectively. In 
addition, in cytokine pre-treated group PFS was longer in pazopanib treated than in 
placebo group (7.4 months vs. 4.2 months), as well as without cytokine treatment (11.1 
months vs. 2.8 months). Adverse events, such as diarrhea, hypertension, nausea, 
anorexia and vomiting were reported (Sternberg et al., 2010). OS was not statistically 
significant in patzopanib treated compared to placebo group (22.9 months vs. 20.5 
months, respectively) (Table 1.) (Sternberg et al., 2013). The safety and efficacy of 
pazopanib and sunitinib as first line therapy were compared in a randomized phase III 
trial (Motzer et al., 2013b). The results demonstrated similar results between patients 
receiving pazobanib and sunitinib: The median PFS was 8.4 months in pazopanib 
treated, and 9.5 months with sunitinib group. Also, there was no difference in OS 
(pazopanib 28.4 months vs. sunitinib 29.3 months). Instead, pazopanib was better 
endured: the quality of life and safety of the treatment favoured pazopanib (Motzer et 
al., 2013b).  Supporting these results, recently published double-blind cross-over study 
of patient preference or quality of life for sunitinib or pazopanib demonstrated that 
pazopanib was the more preferred treatment (61% physicians, 70% patients) (Escudier 
et al., 2014a).  
Bevacizumab is a monoclonal Ab to inhibit VEGF (Escudier et al., 2007b), and it has 
shown clinical benefit in phase II trials: PFS was significantly longer in the patient 
group treated with bevacizumab than in placebo group (4.8 months vs. 2.5 months, 
respectively) (Yang et al., 2003). Afterwards, in a randomized double-blind phase III 
trial bevacizumab treatment was combined with interferon-α, and compared with 
placebo and interferon-α (Escudier et al., 2007b).  The median PFS was significantly 
longer in bevacizumab plus interferon-α treated (10.2. months) than placebo plus 
interferon-α treated (5.4 months) patient group. Instead, the median OS was not 
significantly longer between bevacizumab (23.3 months) or placebo (21.3 months) 
groups (Table 1.) (Escudier et al., 2010). In another phase III trial OS, ORR and safety 
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of bevacizumab plus interferon-α treatment was compared to interferon-α alone (Rini 
et al., 2010). Also in this study, median OS was not significantly longer in 
bevacizumab plus interferon-α treated (18.3 months) than in control group (17.4 
months). Interestingly, patients receiving bevacizumab plus interferon-α treatment and 
with hypertension, had significantly improved PFS and OS compared with patients 
without hypertension, suggesting that hypertension might be a potential biomarker in 
bevacizumab targeted therapies (Rini et al., 2010).  
Sorafenib is an oral multikinase inhibitor for VEGFR, PDGFRβ, FMS-like tyrosine 
kinase 3 (Flt-3), c-Kit protein and RET tyrosine kinases (reviewed in Escudier et al., 
2007a). In phase III trials, sorafenib was effective compared to placebo control group. 
PFS was 5.5 months in sorafenib treated and 2.8 months in placebo group, partial 
response (PR) reports as the best response, but no difference in OS (19.3 with 
sorafenib vs. 15.9 months with placebo) (Table 1.) (Escudier et al., 2007a). In another 
phase II trial, where the effect of sorafenib was compared with interferon-α or 
treatment-naïve RCC patients, PFS was similar between sorafenib and interferon-α 
treated groups. Instead, in sorafenib treated group, tumor size reduction was detected 
and the quality of life was better (Escudier et al., 2009). Because of inefficiency of 
sorafenib, the European Society of Clinical Oncology (ESMO) has recommended to 
use a combination of sorafenib and interferon-α as a front-line treatment (Escudier et 
al., 2014b).  
Axitinib is a second-generation VEGFR1, -2, and -3 inhibitor (Rini et al., 2011). In a 
phase III randomized trial the effect and safety of axitinib and sorafenib as a second-
line therapy were compared in mRCC patients treated first-line with sunitinib, 
bevacizumab plus interferon-α, temsirolimus, or cytokines (Rini et al., 2011). The 
median PFS was significantly extended with axitinib (6.7 months) compared to 
sorafenib (4.7 months). The most common adverse events in the axitinib treated 
patients were diarrhoea, hypertension, and fatigue, and in the sorafenib treated group 
diarrhoea, palmar-plantar erythrodysaesthesia, and alopecia (Rini et al., 2011). No 
difference in OS was detected between axitinib (20.1 months) and sorafenib (19.2 
months) treated groups (Table 1.) (Motzer et al., 2013a). In addition, there was no 
difference in PFS between axitinib and sorafenib groups in first-line treated RCC 
patients (Hutson et al., 2013).  
2.5.3. Mammalian target of rapamycin (mTOR) inhibitors 
The activity of the mTOR is tightly regulated in normal cells, but its activity is 
abnormal in tumors (Vogt, 2001). mTOR is a one of the key components and 
regulators of intracellular pathways such as Akt (cellular survival), PKCα 
(cytoskeletal dynamics), serine/threonine-protein kinase  (SGK1, ion transport and 
growth), and mTOR participates in tumor cell proliferation, survival, growth and also 
angiogenesis (Kapoor and Figlin, 2009). mTOR activity is increased by PI3K/Akt, 
EGF and Ras/MAPKs during tumorigenesis (Vogt, 2001, reviewed in Kapoor and 
Figlin, 2009). Activated mTOR induces the phosphorylation of components of the 
eukaryotic initiation factor 4E-binding protein 1 (4EBP-1) and the translation-
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regulating factors ribosomal S6 kinase 1 (S6K1), which participate in cell proliferation 
and growth (Gingras et al., 1998, Kapoor and Figlin, 2009). In addition, in the absence 
of VHL, activated mTOR further increases the HIF-1α level via its elevated 
translation, resulting in increased VEGF transcription (Kapoor and Figlin, 2009). 
Hence, mTOR is a potential target for targeted anti-angiogenic therapies, and at the 
present, two rapamycin-related mTOR inhibitors temsirolimus and everolimus are 
now showing significant activities against RCC, and are approved for the RCC 
treatment. 
Temsirolimus is a mTOR inhibitor, and in phase III trial its efficacy compared to 
interferon-α, or combination of both treatments (Hudes et al., 2007). Temsirolimus 
treatment alone improved OS and PFS: the median survival was 10.9 months in 
temsirolimus treated group, 7.3 months in the interferon-α treated and 8.4 months in 
the combination group (Table 1.), and PFS was in the temsirolimus treated 3.8 
months, interferon-α treated 1.9 months, and combination treatment 3.7 months. In 
another study, the effect of temsirolimus to different tumor histology types was 
compared with interferon-α treatment (Dutcher et al., 2009). Temsirolimus had a 
similar response rate compared to interferon-α, but interestingly, in temsirolimus 
treated patients tumor reduction was reported to be 59% with clear cell, and 68% with 
other tumor type vs. 35% with clear cell and 14% in other histologies in interferon-α 
treated patients (Dutcher et al., 2009). Temsirolimus is recommended by ESMO and 
National Comprehensive Cancer Network (NCCN) as first-line treatment for RCC 
patients with poor prognosis (Motzer et al., 2009a, Escudier et al., 2014b).  
Everolimus is an orally administered derivative of rapamycin that forms a complex 
with an intracellular protein FKBP-12 resulting in mTOR inhibition. Everolimus is a 
sequential therapy with promising efficacy for RCC patients with progressed disease 
after the failure of TKI treatments (Motzer et al., 2008). In a phase III randomized 
double-blind placebo controlled trial of everolimus in patients treated with first-line 
sunitinib or sorafenib whom disease had progressed, the PFS was prolonged in 
everolimus treated group (Motzer et al., 2008). Instead, everolimus did not prolong 
the median OS (14.8 months with everolimus vs. 14.4 months with placebo) (Table 
1.) (Motzer et al., 2010).  
Table 1. List of tyrosine kinase- and mTOR inhibitor treatments and trials in RCC. 
Treatment Control group Trial End point Results (months) 
TKI Inhibitors     
Sunitinib Interferon-α Phase III OS 26.4 vs. 21.8 
Pazopanib Placebo Phase III OS 22.9 vs. 20.5 
Bevacizumab + 
Interferon-α 
Interferon-α + 
Placebo 
Interferon-α 
Phase III 
Phase III 
OS 
OS 
23.3 vs 21.3  
18.3 vs 17.4 
Sorafenib Placebo Phase III OS 19.3 vs. 15.9 
Axitinib Sorafenib Phase III OS 20.1 vs. 19.2 
mTOR Inhibitors     
Temsirolimus Interferon-α Phase III OS 10.9 vs. 7.3 
Everolimus Placebo Phase III OS 14.8 vs. 14.4 
 
40 
 
2.6. Prognostic and predictive biomarkers of renal cell carcinoma 
Advances in diagnosis and discovery of a disease may be the reason for the increased 
incidence of RCC. Increased use of cross-sectional imaging facilitates the detection of 
small incidental carcinomas. Better understanding of genomics, heredity, proteomics 
and metabolomics of RCC has shed light for the development of new-targeted 
therapies, as well as diagnostic, prognostic, and predictive biomarkers. Many 
candidate biomarkers show promising results in current studies, but so far none has 
entered clinical use, and little is known who will benefit from RCC targeted therapies 
(Ngo et al., 2014). 
VHL is a potential biomarker because of its downstream proteins are involved in 
angiogenesis, but the predictive value of VHL mutation and outcome is contradictory. 
Poor OS and PFS have been reported in patients with loss-of-function VHL mutations 
(Schraml et al., 2002). Instead, there was no association with VHL alteration and 
MVD, tumour cell proliferation, grade and stage (Schraml et al., 2002). In another 
study, patients with sporadic ccRCC and loss-of-function VHL mutation were found 
to have a significantly decreased OS (P= 0.046) and PFS (P= 0.016), but instead, 
there was no association between somatic VHL alteration and PFS and OS (Kim et al., 
2005a). Smits et al. (2008) also found no prognostic value in alterations of VHL 
mutation in RCC. Instead, Brauch et al. (2000) demonstrated that VHL alterations 
associate significantly with poor staging (pT3) indicating the possibility of VHL to be 
a prognostic biomarker. Choueiri et al. (2008) demonstrated that loss-of-function VHL 
mutations could be a prognostic or predictive biomarker, because patients with VHL 
mutations responded better to VEGF therapy, even though the association was not 
significant. 
VEGF pathway is a potential biomarker, and high VEGF expression in plasma and 
tumor tissue has been reported to correlate with tumor size, stage and grade (Jacobsen 
et al., 2004, Rioux-Leclercq et al., 2007). Also, VEGF expression in tumor was 
correlated with tumor necrosis and progression (Rioux-Leclercq et al., 2007). Plasma 
levels of VEGF, soluble VEGFR2 (sVEGFR2), PlGF, and a soluble VEGFR3 
(sVEGFR3) were analysed from the patients treated with sunitinib, and levels were 
varied according the treatment: 2 weeks after off treatment, the levels of the above 
mentioned proteins tended to return to near-baseline (Deprimo et al., 2007). In another 
study, the effect of sunitinib to the bevacizumab-refractory mRCC patients was 
investigated. In this study, VEGF-C and sVEGFR3 levels were decreased 
with sunitinib treatment and associated with longer PFS and ORR (Rini et al., 
2008).  Recently, in a phase III trial, Harmon et al. (2014) investigated potential 
circulating biomarkers to predict the efficacy of first-line sunitinib versus interferon-
α in mRCC. They found, that baseline VEGF associated with PFS, and sVEGFR3 
associated with both, PFS and OS in sunitinib treated patients. In interferon treated 
patients, IL-8 was associated with PFS. These results indicate that baseline sVEGFR3 
may predict sunitinib efficacy, and baseline VEGF and IL-8 may have a prognostic 
value. In another study, VEGFR2 expression in tumor tissue was significantly 
associated with PFS and response to sunitinib treatment (Terakawa et al., 2013), 
41 
 
whereas Gruenwald et al. (2010) showed that sVEGFR2 failed to correlate with 
clinical response in sunitinib treated patients. 
CAIX shows as a promising biomarker as discussed earlier, instead, Leibovich et al. 
(2007) demonstrated that CAIX is not an independent prognostic marker in RCC 
patients. In addition, in another study serum CAIX level was higher in ccRCC patients 
but did not correlate to survival (Papworth et al., 2010).  
Ki-67 is a cell proliferation marker in oncology and especially in RCC, it has raised 
interest as a prognostic biomarker (Ngo et al., 2014). Few studies have demonstrated 
that Ki-67 predicts poor prognosis in RCC patients (Tollefson et al., 2007, Rautiola et 
al., 2016, Lampinen et al., 2016). 
Cytokine and angiogenic factors produced by tumors have been speculated to 
participate in the disease progression after antiangiogenic therapies (Ngo et al., 2014). 
In vivo study using mouse xenografts demonstrated that increased IL-8 expression was 
associated with sunitinib resistance, and that was inhibited by blocking IL-8 (Huang 
et al., 2010). In humans in a clinical phase II trial of pazopanib, PFS and tumor 
shrinkage was associated with IL-6, IL-8, osteopontin, VEGF, E-selectin and 
hepatocyte growth factor (HGF) levels (Tran et al., 2012). High concentrations of IL-
8, osteopontin, tissue inhibitor of metalloproteinases (TIMP) -1 and HGF were 
associated with shorter PFS (Tran et al., 2012). In a phase II trial of sorafenib, and 
sorafenib plus interferon-α treatment, cytokine and angiogenic factors were 
investigated in mRCC patients, demonstrating correlation of prolonged PFS with 
osteopontin, VEGF, CAIX, collagen IV, VEGFR-2, and tumor necrosis factor-related 
apoptosis-inducing ligand levels (Zurita et al., 2012). 
Genetic variations, such as single nucleotide polymorphisms (SNPs), have been 
identified as biomarkers for the treatment. Patients with SNPs in IL-8, HIF-1A and 
VEGF compared to patients without SNPs had lower response rates and reduced PFS 
when treated with pazopanib (Xu et al., 2011). Garcia-Donas et al. (2011) 
demonstrated that two SNPs in VEGFR3 were associated with reduced PFS in RCC 
patients treated with sunitinib. Interestingly, it has been shown that SNPs in three 
genes involved in sunitib pharmacokinetics (ABCB1, CYP3A5, NR1I3), which for 
example participated in the metabolism of TKI, improved PFS (van der Veldt et al., 
2011). In addition, methylation of CpG islands in five different genes (PITX1, FOXE3, 
TWF2, EHBP1L1, RIN1) could help to predict OS in patients categorised to low and 
high risk groups (Wei et al., 2015). Also, micro RNAs (miRNAs) have been involved 
in several tumorigenic pathways and recently published data suggest that five 
circulating miRNAs can be used clinically in early detection of RCC (Wang et al., 
2015). In addition, Gu et al. (2015) demonstrated that miRNAs, especially miR-21 and 
miR-126 could be prognostic markers in RCC and also, useful therapeutic targets.  
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 AIMS OF THE STUDY 
The aim of the study was to investigate the Ang-Tie system at the molecular level to 
better understand the mechanisms that lead to vessel stabilization, and those that lead 
to leaky vessels involved in tumor angiogenesis and metastasis. Identifying Ang/Tie 
signalling mechanisms should increase the possibilities of targeting the Ang-Tie 
system in anti-angiogenic therapies for the treatment of vascular pathologies and 
cancer. In addition, the determination of disease-specific expression of the Ang-Tie 
pathway components should facilitate their therapeutic targeting and use as 
biomarkers in human disease.  
Specific aims are: 
1) Discover the function of Tie1 and integrins in angiopoietin signalling and Tie1-
mediated regulation of Tie2 in ECs using cell biological and microscopic techniques, 
including fluorescence resonance energy transfer (FRET-FLIM-TCSCP) (publication 
III). 
2) Investigate Ang2 as a potential prognostic and predictive biomarker in mRCC 
(publications I and II) 
3) Investigate the mechanism of action of a therapeutic Ang2 blocking Ab in tumor 
metastasis (publication IV). 
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 PATIENTS, MATERIALS AND METHODS 
Detailed description of the materials and methods can be found in the original 
publications (I-IV). 
The HUCH Ethics Committee (I), and the Ethics Committee at Tampere University 
Hospital (II) and the National Authority for Medicolegal Affairs (II) approved the use 
of tumor samples and the research protocol.  
All experiments that required animal usage were approved by the National Animal 
Experiment Board in Finland at the Provincial State Office of Southern Finland, and 
were performed in accordance with the Finnish legislation regarding use of laboratory 
animals. 
1. Patients and treatments 
1.1. Patients in publication I 
This study contained clinical samples from 136 surgically removed primary tumors 
from mRCC patients who received first-line sunitinib treatment between 2006 and 
2012 in the Department of Oncology, Helsinki University Central Hospital (HUCH). 
No prior targeted therapies were approved. Follow-up data of response to sunitinib 
treatment was available from 126 patients. All clinical data and follow-up record were 
collected from the hospital case records. 
1.2. Patients in publication II 
This study contained clinical RCC tumor samples from 244 RCC patients, who were 
treated by the same clinical practice, and underwent nephrectomy between 1985 and 
1995. Tumor samples were obtained from the archives of Tampere University 
Pathology, and were re-evaluated using the Furman grading system and re-classified 
using Heidelberg classification system. 
2. Materials 
2.1. Cell lines 
Table 2. 
Cell line Description Medium Source Used in 
HUVEC Human umbilical vein 
endothelial cells 
ECBM-MV + 5% 
FCS  
PromoCell III, IV 
BEC Human dermal blood 
endothelial cells 
ECBM-MV + 5% 
FCS  
PromoCell IV 
LEC Human dermal 
microvascular lymphatic 
endothelial cells 
ECBM-MV + 5% 
FCS  
PromoCell IV 
NCI-H460-
LNM35 
Human non-small cell 
lung carcinoma 
RPMI-1640 + 10% 
FCS 
(Kozaki et 
al., 2000) 
IV 
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2.2. Primary antibodies 
Table 3. 
Target Description Application Source Used in 
Ang2 Goat polyclonal IHC, WB R&D Systems I-IV 
Akt Rabbit polyclonal WB Cell Signalling III 
α5-integrin Goat polyclonal WB R&D Systems III 
β-actin Rabbit polyclonal WB Cell Signalling III, IV 
β1-integrin Mouse monoclonal WB Merk Millipore III 
β1-integrin Mouse monoclonal IF Abcam III 
β3-integrin Rabbit monoclonal WB Abcam III 
BCL-2 Mouse monoclonal IHC DAKO II 
CD11b Rat monoclonal IF eBioscience III 
CD31 Mouse monoclonal IHC DAKO I 
CD31 Mouse monoclonal IHC Novocastra Laboratories II 
mCD31 Hamster 
monoclonal 
IF Chemicon III 
mCD31 Rat polyclonal IF, IHC BD Biosciences III, IV 
Cytoceratin7 Rabbit monoclonal IHC Millipore IV 
EEA1 Rabbit monoclonal IF Cell Signalling III 
eNOS (pS1177) Rabbit polyclonal IF Cell Signalling IV 
mEphB4 Goat polyclonal IF R&D Systems III 
Flag-tag Rabbit polyclonal WB Sigma-Aldrich III, IV 
Foxo1 Rabbit monoclonal IF Cell Signalling III 
Human anti-Ang2 Monoclonal, 
humanized 
IF (Leow et al., 2012) IV 
Human anti-Ang2 Monoclonal, 
humanized 
IF (Daly et al., 2013) III 
Human anti-Tie2 humanized IF (Adler et al., 2014) III 
HSC70 Mouse monoclonal WB Santa Cruz Biotechnology III 
Ki-67 Rabbit monoclonal IF Abcam III 
Ki-67 Mouse monoclonal IHC Immunotech SAS II 
Ki-67 Mouse monoclonal IHC DAKO I 
NG-2 Rabbit polyclonal IHC Millipore IV 
Phospo-Akt (Ser473) Rabbit polyclonal WB Cell Signalling III 
Phospho Tie2 Rabbit polyclonal IF R&D Systems III, IV 
Phospho Tyr Mouse monoclonal WB Merck Millipore III 
Phospho Tyr Mouse monoclonal WB Santa Cruz Biotechnology III 
mP-selectin Goat polyclonal IF R&D Systems III 
Tie1 Goat polyclonal IF, WB R&D Systems III, IV 
Tie1 Rabbit polyclonal WB Santa Cruz Biotechnology III 
Tie2 Goat polyclonal IF, IP, WB R&D Systems III, IV 
m/rTie2 Goat polyclonal IF, IP, WB R&D Systems III 
V5-Cy3 Mouse monoclonal IF Sigma Aldrich III 
VEGF R2/KDR/Flk-1 Polyclonal Goat IP, WB R&D Systems III 
vWF Rabbit polyclonal IF DAKO III 
VE-cadherin Mouse monoclonal IF BD Biosciences III, IV 
VE-cadherin Rat (clone 11D4.1) IF BD Biosciences IV 
ZO-1 Rabbit polyclonal IF Invitrogen IV 
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2.3. Lentiviruses 
Table 4. 
Target  Description Sequence in 5’-3’ direction Used in 
β1-Integrin shRNA, cloned in 
pLKO.1 vector 
GCCTTGCATTACTGCTGATAT III 
β3-Integrin shRNA, cloned in 
pLKO.1 vector 
CCTTAGCCTTTGTCCCAGAAT III 
α5-Integrin shRNA, cloned in 
pLKO.1 vector 
CCATGATGAGTTTGGCCGATT III 
Tie1 shRNA, cloned in 
pLKO.1 vector 
GACTGGAGCAACACAGTAGAA 
 
III 
2.4. Retroviruses 
Table 5. 
Retrovirus Description Source Used in 
FL-Tie2-GFP Encodes for C-terminal Tie2-
GFP fusion protein 
(Saharinen et al., 2008) III, IV 
Tie2-ΔJM-GFP Encodes Tie2 ectodomain (Hakanpaa et al., 2015) III 
Tie1-ΔIC-V5 Encodes Tie1 ectodomain (Korhonen et al., 2016) III 
VE-cadherin-V5 Encodes VE-Cadherin-V5 tag 
fusion protein 
(Korhonen et al., 2016) III 
Tie1-mCherry Encodes for C-terminal Tie1-
mCherry fusion protein 
(Korhonen et al., 2016) III 
 
2.5. Recombinant proteins 
Table 6. 
Recombinant 
protein 
Description Source Used in 
rhAng1 Recombinant human 
Angiopoietin-1 
R&D Systems III 
rhAng2 Recombinant human 
Angiopoietin-2 
R&D Systems III 
Comp-Ang1 The N-terminal portion of Ang1 
replaced with the short coiled-
coil domain of COMP 
(Cho et al., 2004), a 
kind gift from Dr. Koh, 
KAIST 
III 
VEGF Human VEGF A kind gift from Dr. 
Michael Jeltsch, 
Helsinki 
III 
 
2.6. Mouse lines and viruses 
Detailed description of mouse lines and viruses used in mouse experiments are found 
in the original publications (III, IV). 
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Table 7. 
Mouse line Description Source Used in 
VE-cadherin-
tetracyclin 
transactivator 
(tTA) 
Overexpresses tTA under the 
Cdh5 promoter in ECs 
(Sun et al., 2005) III, IV 
TetO-Ang2 Inducible Ang2 expression driven 
by tTa 
(Holopainen et al., 
2012) 
III, IV 
Tie1 fl/fl loxP-flanked 1st exon of the Tie1 
gene 
(D'Amico et al., 
2014) 
  
III 
Tie1LacZ/+ Tie promoter-driven β-
galactosidase (Lacz) 
(Puri et al., 1995) III 
Pdgfb-iCreERT2 Tamoxifen-inducible form of Cre 
recombinase under Pdgfb 
promoter 
(Claxton et al., 2008) III 
Cdh5(PAC)-
CreERT2 
Tamoxifen-inducible Cre deletor 
under the VE-cadherin 
(Cdh5(PAC)) promoter 
(Wang et al., 2010) III 
Tie1-tTA Overexpresses tTA under Tie1 
promoter in EC 
(Sarao and Dumont, 
1998) 
III 
 
2.7. Cell culture (III, IV) 
EC lines (Table 2.) were maintained in the appropriate Endothelial Cell Basal Medium 
(ECBM) MV (PromoCell) containing the following supplements: 5% Fetal Calf 
Serum (FCS), hEGF (10 ng/ml), Hydrocortisone (1 μg/ml), and Endothelial Growth 
Supplement 0.4% (PromoCell). LECs were grown in ECBM-MV media supplemented 
with VEGF (100 ng/ml). Cell culture plates were coated with gelatin (0.1%) for 
HUVECs and LECs, and with fibronectin (1 μg/ml) for blood vascular endothelial 
cells (BECs). 
3. Methods 
3.1. Cell stimulations (III, IV) 
Confluent cells were starved for 3-5 hours in ECBM-MV media containing 1% FCS 
(PromoCell). After starvation, cells were treated with Ang1 (100-500 ng/ml), Ang2 
(100-500 ng/ml) or Comp-Ang1 (200-500) ng/ml. 
3.2. Viral vector delivery (III, IV) 
Approximately 50% confluent ECs were transduced with retroviral vectors expressing 
genes of interest (Table 5.) in the presence of 0.1% polybrene (Sigma-Aldrich). 5 
hours after adding of the viral vectors, culture media was added, and fresh media was 
changed after overnight incubation. Lentiviral vectors coding for shRNA were used to 
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silence genes of interest in 50-90% confluent EC cultures in the presence of 0.1% 
polybrene (Sigma-Aldrich) (Table 4.). Cells were supplied with fresh media next day 
after transduction. 
3.3. In vivo treatments (III, IV) 
The Tie1fl/fl, Tie1LacZ/+, Pdgfb-iCreERT2, Cdh5(PAC)-CreERT2, VE-cadherin-tTA 
(Cdh5-tTA), Tie1-tTA and tetO-Ang2 were used in original publication III (Table 7.). 
Inducible inactivation of Tie1 (Tie1fl/fl, Tie1LacZ/+) was performed with endothelial-
specific deletors Pdgfb-iCreERT2 and Cdh5(PAC)-CreERT2 by daily administration of 
tamoxifen (2mg/mouse/d) for 5 days, and Cre-positive Tie1fl/fl, Tie1LacZ/+ were 
compared with Cre-negative Tie1fl/fl, Tie1LacZ/+ mice.  
Double-transgenic Ang2 overexpressing mice were obtained via breeding the driver 
Cdh5-tTA or Tie1-tTA with the responder tetO-Ang2 transgenic mouse line (III, IV) 
(Table 7.). Administration of 2 mg/ml of tetracycline in 5% sucrose in the drinking 
water of pregnant females was used to suppress Ang2 expression. Expression of Ang2 
was induced for 2 to 3 months after birth, and serum Ang2 level was increased 25 fold 
compared to WT mice. WT or single transgenic mice were used as controls (III, IV). 
Tie1 deletion in Ang2EC mice was obtain by tamoxifen administration 3 times per week 
for 2-3 weeks to Pdgfb-iCreERT2 Tie1fl/fl Cdh5-tTA tetO-Ang2 mice (III). 
Ad-control (empty control or LacZ), Ad-Comp-Ang1 or Ad-Ang2 (mAng2) 
adenovirus vectors (1 x 109 PFUs/mouse) in 100 μl PBS were injected into tail vein 
of control or Tie1-deficient mice, and after 2 days or 2 weeks, tracheas, lungs and 
serum were collected for analysis (III). 
LPS (15 mg/kg, E.coli LPS055:B5, Sigma-Aldrich) i.p. injection was used to induce 
the endotoxemia in mice,  and 0.5, 1, 3, 6, 12 or 16 hours after LPS treatment mice 
were sacrificed (III). 
3.4. Cell sorting and flow cytometry (III) 
For FLIM, HUVECs transduced with retroviral vectors coding for the GFP tagged 
Tie2 ectodomain, were sorted using fluorescence-activated cell sorting (FACS) Aria 
II Flow Cytometer according to hTie2 expression levels. In brief, HUVECs were 
detached using Accutase (Biosera) for 2 minutes, washed with Dulbecco’s phosphate-
buffered saline (DBPS, Lonza), sentrifuged 1300 rpm for 3 min, and suspended in 
PBS (filtered to the FACS tube) for FACS sorting. HUVECs with low expression level 
of Tie2 (lowest 30% of the transduced HUVEC population) were plated and 
transduced with a retroviral vector coding for the V5 tagged membrane-bound Tie1 
ectodomain. Transduced cells were FACS sorted according to Tie1, by staining the 
cells using the anti-hTie1 Ab (R&D Systems) diluted in 1% Bovine Serum Albumin 
(BSA) (Biotop Oy) in PBS for 20 min on ice. The cells were washed with PBS, and 
incubated with secondary Alexa Fluor 647 Donkey Anti-Goat IgG (Life 
Technologies) diluted to 1% BSA-PBS on ice for 15 min, washed with PBS and 
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subjected to FACS sorting. HUVECs, which expressed medium levels of Tie1 (mid 
30% of the cell population) were used for FLIM experiments. 
3.5. Immunofluorescence staining (III, IV) 
Cells plated on cover slips were fixed with 4% PFA (paraformaldehyde), 
permeabilized (0.1% Triton-X in PBS), and blocked with 1% BSA-PBS, and 
incubated with primary Abs (Table 3.) diluted in blocking buffer. Subsequently, the 
cells were stained with fluorescently labelled secondary Abs (Alexa Fluor, Life 
Technologies) and for nuclei using Hoechst and mounted using Mowiol-Dabco 
(Sighma-Aldrich) or Vectashield (Vector Laboratories) with DAPI (IV). For FLIM 
and FRET (III), cells were stained with anti V5-Cy3 labeled Ab (Sigma-Aldrich) and 
mounted with Vectashield (Vector Laboratories) without nuclear staining. 
3.6. Immunoprecipitation and Western blot (III) 
ECs were lysed in a lysis buffer including 5% glycerol, 1% Triton X-100, 150 mM 
NaCl, 1 mM EGTA, 1.5 mM MgCl2, 100 nM NaF, 10 mM Na4P2O7 . 10 H2O, 50 mM 
Hepes, 1 mM Na3VO4, PMSF, leupeptin and approtinin. Protein concentration was 
analysed using the Pierce BSA Protein Assay kit (Thermo Fisher Scientific). Equal 
amount of protein was immunoprecipitated over night with primary Abs (Table 3.), 
and using protein G-sepharose for one hour (GE Healthsciences Ab). Protein 
complexes or total lysates were separated with sodium dodecyl sulphate 
polyacrylamide gel electrophoresis (SDS-PAGE) (7.5%, 4-20% gradient Ready-Gels, 
Bio-Rad) and transferred to PVDF membrane (TransBlot Turbo Midi-size, Bio-Rad) 
using Transblot Turbo (Bio-Rad) transfer system with manufacturer’s instructions. 
Membranes were blocked (5 % BSA in PBS + 0.1% Tween) and incubated over night 
with primary Abs (Table 3.) at +4oC, washed, blocked and incubated with biotinylated 
secondary Abs and with streptavidin horseradish peroxidase (HRP) (GE-Healthcare), 
or with HRP-conjugated secondary Abs. Signal was detected with SuperSignal West 
Pico or SuperSignal West Femto kit (Thermo Fisher Scientific) 
3.7. Microscopy, confocal microscopy, live cell imaging and image analysis (I-
IV) 
Bright field images from IHC sections (I) were acquired using a Leica DM LB 
microscope (Meyer Instruments) with Olympus DP50 camera using 10x (NA 0.25), 
20x (NA 0.4) and 40x (NA 0.65) objectives with magnification x100, x200 and x400, 
respectively. 
Bright field images from the IHC tissue microarray (TMA) sections (II) were scanned 
using the Panoramic FLASH II (3DHISTECH Ltd) with 40x objective. The 
HistoQuant image analysis software module (3DHISTECH) was used to measure the 
Ang2 positive area from digital images. Nonspecific or low quality of staining (broken 
or detached tissue) was excluded.  
49 
 
Immunofluorescent samples were imaged using a confocal laser-scanning microscope 
(LSM) Zeiss LSM 780 or LSM 880 with Airyscan (III) using the Zeiss ZEN 2 
software, or Zeiss LSM 5 Duo (IV) confocal microscope (Carl Zeiss). 3-dimensional 
projections were digitally reconstructed from confocal z-stacks using the LSM 
software. ImageJ (National Institutes of Health, USA) software was used for area-
based image quantifications. 
Time-lapse imaging (III) was performed using Zeiss LSM 880 (Carl Zeiss) equipped 
with an environmentally controlled incubator (CO2 5%, +37oC) (PM S1), with 63x 
Plan Apochromat Oil-immersion objective (NA 1.40) and time-lapse Z-stack images 
were taken every 20 seconds. Z-stacks were imaged before and after stimulation. 
Time-lapse movies were created using Zeiss ZEN 2 software. 
3.8. FLIM and FRET (III) 
FRET acceptor photo bleaching was performed using Leica TCS SP2 (Leica 
Microsystems) confocal microscope with 63x HCX PL APO CS oil-immersion 
objective NA 1.40 or Leica TCS SP8 (Leica Microsystems) confocal microscope with 
63x HC PL APO CS2 oil-immersion objective NA 1.30 (β1-integrin silenced cells). 
Excitation wavelengths of 488 nm (argon laser) and of 561 nm (DPSS laser) for GFP 
and Cy3, respectively, were used. Fluorescence emissions at 500–530nm for GFP, and 
570–632nm for Cy3 were recorded. Regions of interest (ROI) were chosen after 
angiopoietin stimulation at EC-EC junctions and on cell membrane. For acceptor 
photobleaching ROI was imaged at 100% of DPSS laser power as long as the Cy3 
fluorescence intensity decreased to 0-15% intensity (monitored by the Leica software). 
Pre- and post-bleach images were recorded for both donor (GFP) and acceptor (Cy3). 
FRET efficiency was calculated as FRETEff = (Dpost − Dpre) / Dpost, where Dpre 
and Dpost is the donor (GFP) intensity before and after acceptor (Cy2) photo 
bleaching. When Dpost > Dpre, the FRETEff was considered as a positive. GFP 
intensity was verified outside the bleached area before and after bleaching. 
3I Marianas (3I intelligent Imaging Innovations) fluorescence microscope with 63x 
Alpha Plan-Apochromat Oil immersion objective NA 1.46 and 488nm solid-state laser 
modulated at 50 MHz was used to perform Frequency Domain FLIM. Semrock 
LF488-B filter set was used to exite the donor (GFP). Images were processed using 
Slidebook 5.5 software, and the lifetimes were calculated from selected ROI. 
3.9. Time-Correlated Single Photon Counting (TCSPC) (III) 
Time-resolved fluorescence measurement was performed using the Zeiss LSM 880 
with 63x Plan-Apochromat Oil-immersion objective NA 1.40, equipped with a FRET 
module. A pulsed PDL 800-D Diode laser driver modulated at a repetition time rate 
of 40 MHz was the excitation source, and GFP was excited with a wavelength of 485 
± 10 nm (LDH-D Series, PicoQuant). Photon counting was performed until 60 000-
100 000 photons were counted. Data analysis was performed using SymPhoTime64 
software to measure the fluorescence lifetime of GFP from ROI.  
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3.10. Immunohistochemistry (I, II) 
IHC staining was performed on 5μm, formalin-fixed paraffin-embedded tumor 
tissues. Tissues were deparaffinized (Tissue-Tek, Tissue Clear Xylene substitute, 
SAKURA), rehydrated, and stained using the Tyramide Signal Amplification kit 
(PerkinElmer) following the manufacturer’s instructions. Antigen retrieval was 
executed using 2100-Angtigen Retriever (Aptum Biologics Ltd.) (II) at 120o for 20 
minutes, or microwaves (I) at 750 W for 5 min, and subsequently at 450 W for 10 min, 
in 10 mM citrate buffer (1.8 mM citric acid, 8.2 mM sodium citrate). 10% hydrogen 
peroxidase were used to block endogenous peroxidase activity, and nonspecific 
binding was blocked using TNB (0.5%) blocking buffer (Perkin Elmer). Ang2 
expression and blood vascular endothelium were detected using human Ang2 (R&D 
Systems) (Figure 5.) and a mouse monoclonal Ab to human CD31 (DAKO (I) or 
Novocastra Laboratories (II)) (Table 3.), and biotinylated anti-goat or anti-mouse 
secondary Abs (Vector Laboratories) diluted in TNB. Signal was detected using AEC 
(3-amino-9ethylcarbatzole) chromogen method. Sections were counterstained with 
Mayer’s Hemalum Solution (Merck KGaA).  
 
 
. 
 
Figure 5. Ang2 immunohistochemical 
(IHC) staining of tissue microarray (TMA) 
of renal cell carcinoma (RCC). Ang2 is 
expressed in tumor endothelium 
 
 
 
Ki-67 IHC was performed using a mouse anti-human Ki-67 mAb (KI-67, DAKO (I) 
or Immunotech SAS (II)) with a Ventana UltraView Dab V3 (Ventana Medical 
Systems) kit with amplification, and a Ventana Bench Mark XT immunostainer 
automate (Ventana Medical Systems) (I).  
3.11. Statistical analyses 
I-II: The IBM SPSS Statistics software for Mac (20.0 (I) and 21.0(II)) (IBM 
Corporation) was used to perform statistical analyses. Kaplan Meyer method was used 
to estimate the PFS and OS (I-II).  Age- and gender-adjusted univariate and 
multivariate survival analyses were performed using the Cox proportional hazards 
model (II), and Pearson χ2 test was used to analyse the differences between categorical 
variables (II). Long-rank test was used to analyse and compare survival between the 
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groups, and Fisher’s exact test or Chi-squared test to analysed frequency tables of 
clinic-pathological parameters (I). All tests were two-tailed (I). P values less than 0.05 
were considered as statistically significant.  
III: SPSS or Prism Statistical (GraphPad Software) analysis was used to perform 1-
way ANOVA, followed by Tukey’s, Dunnett’s or Fisher’s least significant difference 
(LSD) test, or Student’s t 2-tailed test. Welch’s t test (2 tailed, unequal variance) 
followed by Bonferroni’s correction was used for pairwise comparisons of FLIM and 
FRET measurements. P values less than 0.05 were considered as statistically 
significant.  
IV: Statistical analysis of metastasis occurrence was performed with Fisher exact test, 
and the analysis of primary tumor growth curves was performed using one-way 
analysis of variance. All tests were two-sided. P values less than 0.05 were considered 
as statistically significant.  
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 RESULTS AND DISCUSSION 
There has been a significant interest to utilize the Ang-Tie system as a target for future 
anti-angiogenic therapies and several investigational drugs targeting this system are in 
clinical trials. However, the signalling mechanisms of Angs and the function of the 
orphan Tie1 receptor are not fully understood, creating uncertainty how to best 
develop Ang-Tie targeted therapeutics. Identifying the signalling mechanisms of the 
Ang-Tie pathway should increase the possibilities for its therapeutic targeting for the 
treatment of vascular pathologies and cancer. Here, we investigated the Ang-Tie 
system at the molecular level to better understand the mechanisms that lead to vessel 
stabilization, and those that lead to leaky vessels involved in tumor angiogenesis and 
metastasis, as well as in inflammation. In addition, determination of the expression of 
the Ang-Tie pathway components in human disease, including different cancers, will 
lead to more comprehensive understanding of the role of this vascular system in 
human disease, potentially guiding future decisions of cancers where the Ang-Tie 
system might be best targeted.  
1. Tie1 participates in angiopoietin signalling in vivo and in vitro (III) 
As described above, Ang1 can act as a Tie2 agonist, which promotes vascular 
stabilization in cancer, but also in inflammation and sepsis, whereas Ang2 can act as 
a context-dependent Tie2 agonist or antagonist. In our original publication III we 
investigated the function of Tie1 in angiopoietin signalling and vascular remodelling. 
For this we used EC cultures to investigate molecular mechanisms of Tie1-Tie2 
signalling complex formation, transgenic mice expressing Ang2 in the vascular ECs, 
and EC specific Tie1 deletion in adult mice to study in vivo vascular functions of Ang2 
and Tie1, and compared the effects with adenoviral delivered Ang1 and Ang2. In 
addition, we investigated the changes in Tie signalling in inflammation following LPS 
and TNF-α administration in mice.  
2. Tie1 is required for Angiopoietin-mediated vascular remodelling 
(III) 
Previously, it has been shown that adenoviral vector delivery of Ang1 and Ang2 
induced tracheal vascular remodelling (Kim et al., 2007). To confirm these results, we 
injected adenoviral Comp-Ang1 (Ad-CAng1) and native Ang2 (Ad-Ang2) to WT 
mice and found enlargement of the tracheal vessel after both stimulations, although 
the effects were much stronger in Ad-CAng1 treated mice. Interestingly, vessel 
enlargement was not found in Tie1 deficient and Ad-CAng1 or Ad-Ang2 treated mice 
indicating that Tie1 is involved in angiopoietin induced tracheal vessel remodelling. 
Also, the venous markers Ephrin B4 (EbhB4) and P-selectin were decreased in the 
trachea of the Tie1 deficient mice after Ad-CAng1 or Ad-Ang2 treatment compared 
to control, where expression levels were strong in remodelling capillaries. Previously, 
the expression of venous markers induced in inflammation has been shown to increase 
after Ang1 stimulation (Fuxe et al., 2010). Also, we found that Tie1 silencing in 
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cultured ECs using shRNA lentivirus and Tie1 deletion in mouse EC reduced 
proliferation after angiopoietin stimulation when compared to corresponding 
treatments in control, Tie1 expressing ECs in vitro and in vivo. These results indicate, 
for the first time, that Tie1 is necessary for angiopoietin induced EC proliferation 
leading to vessel enlargement and remodelling. 
3. Angiopoietin induced Tie2 phosphorylation and Foxo1 inactivation 
is impaired in Tie1 deficiency (III) 
Ad-CAng1, but not Ad-Ang2, induced the phosphorylation of Tie2 in lungs, as 
observed in Western blotting of lung lysates. Tie2 phosphorylation was less in Tie1 
deficient mice after Ad-CAng1 treatment. Also, Tie2 downstream signalling via the 
Akt serine kinase was less activated in Tie1 deficient, Ad-CAng1 treated mice when 
compared to control, Ad-CAng1 treated mice. In Tie1 silenced and Ang1 stimulated 
cultured ECs, Foxo1 was detected in nucleus indicating the activation of Foxo1, and 
a similar effect was detected in vivo in mouse trachea. Foxo1 was excluded from the 
nucleus and present in the cytoplasm in control, Ang1 -treated ECs and WT mice 
resulting in decreased levels of Foxo1 target gene expression including the endothelial 
cell specific molecule 1 (Esm-1) and Ang2, and this effect was less in Tie1 deficient 
mice. Foxo1 target gene activation is associated with angiopoietin-induced vascular 
proliferation and enlargement in normal conditions, but the effect of Tie1 for Foxo1 
activation has not been previously discussed. Transgenic expression of Ang2 in mouse 
ECs induced phosphorylation of Tie2 indicating that endogenous Ang2 is an agonist 
of Tie2. The differential effect of autocrine Ang2 and Ad-Ang2 on Tie2 activation 
may be due to various oligomeric forms of recombinant Ang2, the stoichiometry of 
the agonist Ang2 is not known. Also, Ang2 concentration and stimulation time may 
affect Ang2 activity as a Tie2 agonist (Teichert-Kuliszewska et al., 2001).  
4. Ang2 acts as a Tie2 antagonist in inflammatory conditions (III) 
To investigate Tie signalling in inflammation we treated mice with LPS or TNF-α. 
LPS treatment decreased tracheal Tie2 and Tie1 expression in mice. Tie2 was also 
decreased in the lung, as determined using Westerns blotting of lung lysates, resulting 
in decreased Tie2 and Akt phosphorylation and increased nuclear Foxo1 in tracheal 
vessels. Decreased Tie2 levels are in line with previous results (Mofarrahi et al., 2008). 
The levels of Ang2, which is a target of Foxo1 -mediated transcription, were increased 
in serum after LPS treatment. However, this did not induce Tie2 phosphorylation, 
demonstrating that Ang2 is an antagonist of Tie2 in inflammatory conditions. Previous 
studies have shown, that blocking Ang2 protects the vasculature in sepsis (Ziegler et 
al., 2013, Han et al., 2016). 
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5. Tie1 ectodomain is cleaved in inflammation leading to a loss of 
agonistic effects of Angiopoietins (III) 
We also found the cleaved Tie1 ectodomain in mouse serum after LPS treatment. 
Interestingly, the sTie1 levels were also significantly increased in patients with acute 
Puumala hantavirus infection compared to healthy controls. TNF-α treatment also 
induced Tie1 cleavage in vivo, which is in line with Singh et al (2012) study, where 
they showed that Tie1 was cleaved after TNF-α treatment of cultured ECs. Ad-CAng1 
treatment induced less Tie2 phosphorylation in the lungs after LPS administration of 
mice when compared to Ad-CAng1 treatment alone. Also, LPS treatment abolished 
Tie2 phosphorylation in the transgenic mice expressing Ang2 in ECs. These results 
support a concept that Tie1 ectodomain is required for the agonistic effects of 
angiopoietins for Tie2 activation. Interestingly, a 2-day treatment of mice with Ad-
CAng1 before LPS administration, decreased the leakiness of blood vessels and 
circulating Ang2 levels and increased Tie1 levels in tracheal vessels and lung, 
suggesting that pre-treatment with Ang1 protected the vasculature via inhibiting the 
loss of Tie1 ectodomain under inflammatory conditions. These results are in line with 
Kim et al. (2016) and David et al. (2011) where they showed that Ang1 stabilized the 
endothelial barrier function and vascular leakiness in a murine model of Mycoplasma 
pulmonis and sepsis, respectivlely. 
6. Direct interactions of Tie1 and Tie2 are induced by angiopoietins 
(III) 
Tie1 does not bind angiopoietins but it has been reported to co-immunoprecipitate 
with Tie2, and Tie1 is also phosphorylated by Ang1 via Tie2 (Saharinen et al., 2005, 
Yuan et al., 2007). Ang2 induces significantly weaker Tie receptor activation when 
compared to Ang1, even though Ang2 also promotes Tie receptor localization to EC-
EC junctions (Maisonpierre et al., 1997, Saharinen et al., 2008). Therefore, we decided 
to investigate how Tie1 is coupled to Tie2 signalling by analyzing direct Tie1 and Tie2 
interactions, within a 10 nm distance, in intact cells after angiopoietin stimulation. For 
this we set up three different methods: 1. FRET based on acceptor photobleaching, 2. 
FLIM analyzed using frequency domain microscope and 3. TCSPC-FLIM. Three 
methods were used, since FRET based on acceptor photobleaching is affected by 
donor concentrations, creating possible bias, whereas TCSPC-FLIM directly measures 
photons emitted from an excited donor, thereby giving most exact information about 
the surrounding and the subcellular localization of the donor fluorochrome. I was able 
to set up TCSPC-FLIM technology at my department, after the purchase of the FLIM 
module with a pulsed laser source of illumination and its installment of the LSM 880 
Airyscan.  
6.1. FRET based on acceptor photobleaching 
Hence, we hypothesized that Ang1 and Ang2 induce dissimilar Tie1-Tie2 interaction 
leading to different downstream signalling. As described above, our previous results 
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have shown that Tie1 and Tie2 co-localize in ECs following Ang1 or Ang2 stimulation 
(Saharinen et al., 2005, Holopainen et al., 2012). To analyze Tie1-Tie2 interaction at 
the molecular level, we set up FRET method based on acceptor photo bleaching that 
detects short distance (10 nm) molecular interactions. For FRET, we created ECs 
expressing membrane-bound Tie1 and Tie2 ectodomains that were intracellularly 
tagged with V5 and GFP respectively, considering the optimal length of the receptor 
cytoplasmic domains for FRET. ECs were treated with angiopoietins and V5 was 
detected using Cy3-conjucated anti V5 Ab. Using the FRET method, we showed a 
statistically significant FRET efficiency between Tie1 and Tie2 following Comp-
Ang1 (29.1% ± 5.6%), Ang1 (29.2% ± 6.8%) and Ang2 (31.8% ± 5.6%) stimulations. 
In contrast, FRET efficiency in control untreated cells was 15.0% ± 6.4%.  
To exclude any potential bias in the results due to variation in Tie1/Tie2 expression 
levels achieved via retroviral expression, we decided to measure the FRET efficiency 
from retroviral transfected HUVECs after FACS sorted according to Tie2 and Tie1 
expression. HUVECs were sorted according to Tie expression to create cells with 
relatively uniform but low Tie2 expression levels and high Tie1 expression levels. 
High acceptor concentration is likely to increase weak FRET efficiency when acceptor 
photobleaching is used. 
However, we found no difference in FRET efficiency following Comp-Ang1 (32.1% 
± 5.4%), Ang1 (30.4% ± 2.7%) and Ang2 (29.2% ± 6.8%) stimulations of HUVECs 
where Tie receptor levels were adjusted, confirming our previous results. Again, 
FRET efficiency in control, untreated cells was 15.0% ± 6.4%. Tie1-V5 and a 
membrane-anchored GFP were used as a control FRET pair. No interaction was 
detected after angiopoietin stimulation between Tie1-V5 and the membrane-anchored 
GFP (FRET efficiency 3.3% ± 0.67%). 
6.2. Frequence domain FLIM 
We next used frequency domain FLIM to further verify our data, as this method is less 
sensitive to variations in donor expression level. In HUVECs sorted according to Tie 
receptor expression as above, the established GFP-lifetime (2.0 ns) was significantly 
decreased in EC-EC junctions in Comp-Ang1 (1.68 ns ± 0.09 ns), Ang1 (1.64 ns ± 
0.07 ns) and Ang2 (1.65 ns ± 0.06 ns) stimulated cells compared to unstimulated cells 
(1.89 ns ± 0.07 ns). As a control, we used HUVECs expressing low level of Tie2 
together with V5-tagged VE-cadherin. In Tie2-VE-cadherin transfected cells there 
were no significant differences in GFP-lifetimes between unstimulated (2.0 ± 0.1ns), 
Comp-Ang1 (1.95 ± 0.09ns), Ang1 (1.9 ± 0.09 ns) or Ang2 (1.88 ± 0.07 ns) ECs, 
indicating that Tie2 and VE-cadherin do not interact despite the localization of both 
proteins in cell-cell junction. As expected, with this method we were able to reduce 
the variation in the results. 
6.3. Summary of FRET and FLIM results 
The results using the FRET and FLIM indicate that the orphan Tie1 receptor directly 
interacts with Tie2 and this interaction is induced by angiopoietin stimulation, 
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although the angiopoietins only bind to Tie2. This interaction mostly occurs in the EC-
EC junctions, although recombinant Ang1 induced also significant Tie1-Tie2 
interaction in intracellular vesicles. These results are novel and appear to contrast 
some of the previously published results by Seegar et al. (2010), who reported using 
FRET based on acceptor photo bleaching that after Ang1 stimulation, Tie1 dissociates 
from Tie2. These studies were conducted using U2OS osteosarcoma tumor cells and 
EA.hy926 somatic endothelial-tumor hybrid cells, which may have affected Tie 
receptor trafficking when compared to our results from primary ECs (Seegar et al., 
2010). Thus, our approach utilizes ECs, which are known to be the natural cell type of 
Tie receptor expression and also have well developed EC-EC junctions and EC 
specific junction proteins. Our results of the mode of Tie1-Tie2 interaction being 
induced both by Ang1 and Ang2 are in line with the in vivo results demonstrating that 
both ligands function as agonists in non-inflammatory conditions. The Tie1-Tie2 
interaction was mediated by the Tie receptor ectodomains, which was rapidly cleaved 
from Tie1 in inflammation, correlating with reduced agonist activity of both Ang1 and 
Ang2.   
7. Ang-Tie signalling is dependent on α5β1-integrin (III) 
In addition, we found that the Ang1-induced Tie2 activation and downstream 
signalling is dependent on β1-integrin. Using the TCSPC-FLIM, we further 
investigated the molecular Tie1-Tie2 interactions in ECs where β1-integrin was 
silenced using shRNA lentiviruses (shβ1). We found that the Ang1-induced molecular 
interaction in EC-EC contacts between Tie1 and Tie2 was significantly decreased in 
shβ1 ECs compared to control scramble silenced (shScr) ECs (Comp-Ang1 stimulated 
shScr 1.67 ns ± 0.09 ns vs. CAng1 stimulated shβ1 1.73 ns ± 0.09 ns). Interestingly, 
translocation of endogenous Tie1 and Tie2 to EC-EC junctions was reduced in β1-
integrin silenced ECs, but not in Scr or β3-integrin silenced ECs. Importantly, silencing 
of α5-integrin or β1-integrin, but not β3-integrin, reduced the angiopoietin-induced 
Tie2 and Tie1 tyrosine phosphorylation, serine phosphorylation of the downstream 
Akt kinase, and nuclear exclusion of the Akt target Foxo1 transcription factor. The 
results demonstrating decreased interaction of Tie1 and Tie2 in shβ1 ECs might reflect 
altered complex formation between Tie1 and Tie2 after angiopoietin stimulation. The 
FLIM/FRET method can detect protein-protein interactions that occur within 10 nm 
distance and in the absence of β1-integrin, the Tie receptor complex may have a 
different structure. In contrast to silencing the β1-integrin, blocking Abs that inhibit 
the binding of β1-integrin to fibronectin did not affect Tie2 phosphorylation, 
suggesting a function for β1-integrin distinct of its ECM binding. Furthermore, β1-
integrin silencing did not reduce VEGF-induced VEGFR2 phosphorylation. Our 
results are in line with and extend results by Cascone et al. (2005) who showed that 
Tie2, but not VEGFR-2, co-immunoprecipitated with α5β1-integrin, and that Tie2 was 
not co-immunoprecipitated with α2β1- or αvβ3-integrins. They also demonstrated that 
Ang1-Tie2 signalling was increased in ECs adherent to fibronectin matrix via α5β1-
integrin. In addition, we have shown that Ang2 can directly activate β1-integrin 
resulting in stress fiber formation and subsequent EC destabilization (Hakanpaa et al., 
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2015). Our results indicate for the first time that α5β1-integrin promotes Ang1-induced 
heteromeric complex formation between Tie1 and Tie2, Tie receptor activation and 
downstream signalling. These results call for further studies to explore the function of 
β1-integrin on angiopoietin-induced Tie receptor activation and angiopoietin-induced 
vascular processes in vivo. 
8.  Tie1 is required for Ang2 agonist function (III) 
The function of Tie1 in angiopoietin signalling has remained one of the key questions 
in angiopoietin field that are poorly understood. Therefore, in this study (III) we 
investigated the effect of Tie1 deletion on angiopoietin mediated Tie2 signalling and 
the requirement of Tie1 for the agonistic function of Ang2. As Ang2 is a weak Tie2 
agonist in vitro, we used retrovirally transduced ECs expressing full length Tie2 fused 
via its intracellular domain to GFP (FL-Tie2-GFP). When stimulated with Ang2, Tie2 
phosphorylation can be detected in these cells. shRNA silencing of Tie1 decreased 
Tie2 phosphorylation after Ang2 stimulation when compared to control, shScr 
silenced cells. Interestingly, Tie2 was phosphorylated in the transgenic mice 
expressing Ang2 in ECs, but phosphorylation was not detected in the lungs of Ang2 
transgenic mice in Tie1 deleted background. These results demonstrated that Ang2 is 
a Tie2 agonist, in line with previous studies which showed that autocrine Ang2 acted 
as a weak Tie2 agonist and stabilized ECs in culture (Daly et al., 2006, Yuan et al., 
2009). In addition, our results indicated that Tie1 is necessary for the Tie2 agonistic 
activity of autocrine Ang2 in vivo and contributes in a similar way in cultured ECs.  
9. Tie2 trafficking is altered in the absence of Tie1 (III) 
Angiopoietins induce Tie receptor translocation into EC-EC junctions (Fukuhara et 
al., 2008, Saharinen et al., 2008) and the reduced Tie2 phosphorylation observed upon 
Tie1 silencing may be due to the impaired Tie2 trafficking in ECs. To investigate this 
possibility, we utilized time-lapse videomicroscopy of FL-Tie-GFP expressing 
HUVECs. We found that Tie1 silencing reduced the translocation of FL-Tie2-GFP 
into EC-EC junctions after Ang2 stimulation when compared to control, shScr 
silenced cells. Instead after Ang1 stimulation of Tie1 silenced cells, some of the FL-
Tie2-GFP was translocated into EC-EC junctions, but immediately internalized into 
early endosomes, also from all over the EC membrane. This was confirmed using Abs 
against the early endosome antigen 1 (EEA1). Notably, although Tie1 silencing 
decreased Tie2 translocation into EC-EC junctions, no internalized vesicles were 
detected after Ang2 stimulation.  In line with the results of increased Tie2 
internalization after Ang1 stimulation of Tie1silenced ECs, Tie2 protein in the lungs 
of Ad-CAng1-treated, Tie1 deleted mice was less compared to control, Ad-CAng1 
treated mice.  
Our findings are consistent with previous studies. Savant et al. (2015) demonstrated 
that after Ang1 stimulation of Tie1 silenced HUVECs, Tie2 was internalized into 
lysosomes, detected by colocalization with the lysosomal associated membrane 
protein (Lamp-1), in. Also, the same authors demonstrated that prolonged Ang1 
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stimulation of Tie1 silenced confluent ECs resulted in decreased Tie2 phosphorylation 
and decreased also the total Tie2 protein. Han et al. (2016) also demonstrated that 
Ang1, but not Ang2 induced Tie2 internalization via EEA1 positive endosomes. 
Interestingly, ABTAA, a monoclonal Ang2 Ab with therapeutic properties in murine 
sepsis models, induced strong Tie2 activation and internalization of Tie2. Our results 
further demonstrate that Tie1 is required for the agonist activity of both, Ang1 and 
Ang2 signalling, and that loss of Tie1 affects Tie2 trafficking after stimulation with 
both ligands. Interestingly, Tie2 mutations that cause venous malformations (VM) 
(Limaye et al., 2009) and primary congenital glaucoma (PCG) (Souma et al., 2016) 
have been reported to affect Tie2 trafficking in ECs. Limaye et al. (2009) 
demonstrated that overexpressed somatic L914F mutation of Tie2 in HUVECs was 
abnormally localized in endoplasmic reticulum (ER) in both unstimulated and Ang1 
stimulated cells, and that Ang1 stimulation did not induce Tie2 translocation to the 
EC-EC junctions. Instead, the L914F VM associated Tie2 mutant was 
hyperphosphorylated in a ligand-independent manner. In addition, they found the 
same Tie2 L914F mutant in humans with sporadic VM. Also Souma et al. (2016) 
demonstrated that Tie2 mutants that cause PCG, do not translocate to EC-EC junctions 
after Ang1 stimulation of HUVECs. These results indicate that disease-causing 
mutations that either increase or decrease Tie2 activity can disturb Tie2 trafficking, 
demonstrating the importance of correct Tie2 trafficking in ECs for normal vascular 
responses in vivo. It would be interesting to investigate the potential role of Tie1 in 
the trafficking by the mutant Tie2 receptors. 
10. Ang2 modulates endothelial cell-cell junctions in blood vasculature 
enhancing tumor cell extravasation and metastasis (IV) 
Ang2 has been reported to be upregulated in many cancers and anti-angiogenic drugs 
targeting Ang2 are in clinical phase I-III trials. In this study (IV), we analyzed the 
effect of Ang2 in tumor metastasis in vivo, and the mechanisms of action of a 
therapeutic anti-Ang2 Ab in vitro. Transgenic mice expressing mouse Ang2 in the 
endothelium under doxycycline regulated promoter were used. In addition, 
subcutaneous syngeneic mouse melanoma (B16-F10) and lung carcinoma (LLC) 
models were used as well as human NCI-H460-LNM35 xenografts. Tumor growth, 
angiogenesis and lymphangiogenesis were analyzed, in addition to lung and lymphatic 
metastasis after systemically induced adenoviral Ang2 overexpression, as well as after 
administration of Ang2 blocking Abs.  
Adeno-associated viral Ang2 delivery in mice for three weeks before implantation of 
tumor cells increased primary tumor growth of LNM35 tumor cells and elevated tumor 
lymphatic and blood vessel densities. Also, lymph node and lung metastasis were 
increased. Similar results were obtained using transgenic mice expressing Ang2 in 
ECs: Ang2 expression increased lung metastasis of intravenously injected tumor cells 
in a melanoma model when compared to control mice two weeks after injection. In 
immunodeficient mice, administration of therapeutic anti-Ang2 blocking Abs, but nor 
control Abs, reduced abnormalities of metastasis-associated lung capillaries, including 
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gaps between EC junctions and inhibited tumor metastasis, growth, angiogenesis and 
lymphangiogenesis. 
To investigate the mechanism of action of the therapeutic anti-Ang2 Ab at the 
molecular level, we used BECs ectopically expressing of FL-Tie2-GFP via retrovirus. 
BECs secrete endogenous Ang2, resulting in the Tie2-Ang2 complex formation in EC-
EC junctions. We showed that the anti-Ang2 Ab induced the internalization of Ang2-
Tie2 complexes from EC-EC junctions resulting in decreased junctional Tie2 and Tie1 
receptor localization. The anti-Ang2 Ab decreased Ang2-Tie2 complexes in EC 
junctions but did not affect the Ang1-Tie2 complexes, which are known to improve 
EC adherens junction integrity. Therefore, we investigated the integrity of the vascular 
endothelium in the lungs, where tumor cells had metastasized. We used the transgenic 
mice expressing Ang2 in ECs and WT mice after administration of anti-Ang2 blocking 
or control Abs and analyzed lung samples, using transmission electron microscopy. 
Interestingly, severely disrupted EC-EC junctions and EC detachment from the 
underlying BM were observed in Ang2 overexpressing, tumor cell injected mice 
compared to controls. Furthermore, the anti-Ang2 Ab treatment increased the integrity 
of the adherent EC-EC junctions in the lungs of wild-type mice, where tumor cells had 
extravasated. This was associated with reduced tumor metastasis. Our novel results 
suggest that Ang2 modulates EC-EC junctions, which enhances tumor cell 
extravasation. These effects can be prevented using anti-Ang2 Ab, which may lead to 
a stabilization of the EC-EC junction resulting in decreased tumor metastasis. 
11. Ang2 in renal cell carcinoma (I-II) 
RCC has an increased prevalence world-wide (Rini et al., 2009). RCC is resistant to 
chemotherapy and also, respond poorly to interferon and IL-2, which have been used 
in the treatment of RCC before targeted therapies (Rini et al., 2009, Coppin et al., 
2011). Since 2005, seven targeted therapies have been approved for the treatment of 
mRCC, and as more therapies are coming available, including immune check-point 
inhibitors, understanding of the mechanisms of disease development and knowledge 
of patients that will benefit from these treatments are of great importance. 
11.1. Ang2 is expressed in mRCC tumor endothelium and correlates with vascular 
density (I) 
High circulating Ang2 has been reported to predict poor prognosis in metastatic breast 
and colorectal cancer and in melanoma (Sfiligoi et al., 2003, Helfrich et al., 2009, 
Goede et al., 2010), whereas the expression of Ang2 in the primary tumor tissue has 
not been widely investigated. One of the reasons may have been the lack of suitable 
methods, and few studies have demonstrated Ang2 expression in the neoplastic tumor 
cells. We developed an IHC-based method of detection of Ang2 in human RCC, and 
image based quantification of Ang2-positive tumor vasculature. 
Thus, using IHC, we evaluated the expression of Ang2, CD31 and Ki-67 in clinical 
mRCC tumor samples, in a material containing 136 surgically removed primary 
tumors from mRCC patients who received first-line sunitinib treatment after the 
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surgery and follow-up data of the patients. In this project we investigated for the first 
time if the expression of Ang2 protein in the primary tumor has predictive value for 
sunitinib-treatment response in RCC. This is important because there is a need for the 
identification of biomarkers predicting the sunitinib response, but so far no such 
established markers are in clinical use (Ravaud and Schmidinger, 2013). 
We found that Ang2 was exclusively expressed in the ECs of tumor blood vessels but 
not in tumor cells, and Ang2 expression in the vasculature correlated with vascular 
density as measured by CD31 IHC staining. Few studies demonstrate that high MVD 
in RCC is associated with more aggressive tumors, and predisposes to tumor 
metastasis (reviewed in Baluk et al., 2005) and also, predicts a poor prognosis in 
ccRCC (Joo et al., 2004, Yao et al., 2007). Instead, Virman et al. (2015) recently 
published that low expression of CD31 in RCC was associated with shorter OS. Li et 
al. (2013) demonstrated in their study using IHC that Ang2 is expressed in cytoplasm 
of oral squamous cell carcinoma. Currie et al. (2002) previously showed tumoral as 
well as endothelial expression of Ang2 using IHC in 45 RCC patient samples. In our 
study, we demonstrated the specificity of Ang2 IHC staining using recombinant Ang2 
protein to neutralize the Ang2 Ab before IHC staining, which completely abolished 
the IHC signal. Initial scoring of the samples was based on vessel density in four 
categories (<5 Ang2 positive vessels/microscopic field, 5-50 Ang2 positive 
vessels/microscopic field, 50-100 Ang2 positive vessels/microscopic field and >100 
Ang2 positive vessels/microscopic field). For statistical analysis, the samples were 
grouped to high (included 50 or more Ang2 positive vessels) and low group (included 
less than 50 Ang2 positive vessels in the microscopic field). High Ang2 group 
contained 38% of the samples, and low Ang2 group 62% of the samples. High CD31 
group contained 60% of all samples, with 100 or more CD31 positive vessels per 
microscopic field, whereas the low CD31 group consisted of 40% of the samples. The 
segregation of samples based on CD31 IHC was based on a very clear cutoff of highly 
vascular mRCC tumors.  High Ang2 expression level correlated with high CD31 
expression level (P < 0.0001). 
11.2. High Ang2 expression was correlated with better response to sunitinib 
treatment (I) 
Best response to treatment, including both indicators of stable disease (SD) + PR was 
defined as CBR. When compared to low and high Ang2 expression, CBR was 91% in 
the high Ang2 group when compared to 76% in the low Ang2 expression group (P = 
0.033). Only 9% of patients with high Ang2, compared to 24% of patients with low 
Ang2 expression had progressive disease (PD) as their best response to sunitinib 
treatment (P = 0.033). Also, similar results were observed in the CD31 groups: CBR 
was 94% in high and 74% in low CD31 expression groups (P = 0.005). In line with 
our results, Dornbusch et al. (2013) demonstrated that mRCC patients with high CD31 
expression, had better response to sunitinib treatment. In our study, only 7% of patients 
with high CD31 expression, when compared to 25% of patients with low CD31 
expression had PD as their best response (P = 0.005) to sunitinib treatment. 
Combination of high CD31 and high Ang2 expression predicted more frequently 
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clinical benefit with sunitinib (100% of patients with CBR) when compared to patients 
with low expression of both of the markers (76%) (P = 0.002). None of the patients 
with high CD31 and Ang2 expression levels had PD as their best response to 
treatment. 
High pre-therapeutic Ang2 expression in the tumor vasculature was correlated with 
better response (PR/SD) to sunitinib treatment (P = 0.03). In our study, high 
expression of Ang2 or CD31 did not correlate significantly with PFS or OS. In line 
with these results, SD was not significantly different in patients with low levels of 
Ang2 and CD31 (median 10.5 months) compared to combination of high levels 
(median 8.7 months) (P = 0.626). Interestingly and as expected, our study showed 
significant correlation between clinical benefit (PR/SD) and longer PFS (14.1 months 
for median PFS for PR/SD patients vs. 3.3 months for PD patients, P < 0.0001) and 
also OS was significantly prolonged (30.1 months for PR/SD patients vs. 12.7 months 
for PD patients, P < 0.0001). Although high Ang2 and CD31 did not correlate with 
prolonged PFS and OS, they associated with CBR. 
Recently published data from a clinical phase II trial (146 RCC patients) demonstrated 
that lower circulating Ang2 associated with better response to sunitinib (Motzer et al., 
2014). However, the correlation between circulating and primary tumor Ang2 
expression levels still remains to be investigated. One potential explanation for the 
differential results obtained using IHC and based on serum markers may be that Ang2 
is stored in Weibel-Palade bodies of tumor vascular endothelium, which can be 
detected using IHC, and stored Ang2 level may not correlate with bioactive Ang2 
levels. Stored Ang2 has been supposed to function in an autocrine manner in tumor 
endothelium, thus the correlation of tumor endothelial and circulating Ang2 level in 
human cancer needs more investigation. Also, differences in the levels of VEGF and 
VEGFR2 expression in tumors versus their circulating levels, and association of these 
parameters to response to sunitinib treatment have been reported in smaller studies 
previously. Terekawa et al. (2013) showed in their study including 40 mRCC patients 
that the expression level of VEGFR2 in the tumor tissue detected by IHC was 
significantly associated with PFS and response to sunitinib treatment, whereas 
Gruenwald et al. (2010) showed that soluble VEGFR2 failed to correlate with clinical 
response in sunitinib treated mRCC patients.  
Although sunitinib treatment is known to prolong the median OS (Motzer et al., 
2009b), complete durable responses are rare. This is associated with acquired 
resistance that develops during therapy. On the other hand, patients that do not benefit 
at all are considered to manifest with intrinsic sunitinib resistance. Giuliano et al. 
(2015) demonstrated in vitro, that sunitinib was internalized to the lysosomal vesicles 
(detecting with Lamp-1 Ab), but did not accumulate in early endosomes (detected with 
EEA1 Ab) in mRCC cells. Internalization of sunitinib reduced the activity of sunitinib 
resulting to a drug resistance. It has been proposed that Ang2 expression might induce 
resistance to anti-angiogenic therapies, based on mouse glioblastoma and breast 
cancer models (Scholz et al., 2015, Rigamonti et al., 2014). However, in our study 
high Ang2, as detected using primary tumor IHC, was associated with increased CBR 
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to sunitinib. Further studies are needed to investigate sunitinib resistance in ECs. 
11.3. High Ki-67 expression in tumor cells predicted poor prognosis (I) 
We used 10% Ki-67 positive nuclei as a cut off to categorize Ki-67 groups to high and 
low expression groups. We found a correlation between high pre-therapeutic 
expression of Ki-67 and worse outcome in patients treated with sunitinib. PFS was 6.5 
months in patients with high Ki-67 when compared to 10.6 months in the low group 
(P = 0.009). In addition, a similar trend was observed in OS comparing high (15.7 
months) and low (28.5 months) expression levels of Ki-67 (P = 0.015). Our results 
are in line with previous studies, where high Ki-67 expression in non-metastatic 
ccRCC was associated with poor patient prognosis (Tollefson et al., 2007, Gayed et 
al., 2014). However, our results are to our knowledge first to demonstrate predictive 
value for Ki-67 expression in mRCC, which has been treated with first-line sunitinib. 
11.4. Angiogenesis and proliferation markers Ki-67 and BCL-2 as long-term 
prognostic factors in RCC patients (II) 
To investigate the significance of Ang2 expression on the natural course of RCC, we 
used RCC samples from patients who received no targeted therapy. We evaluated 
Ang2 expression alone and together with cell proliferation and apoptosis markers (Ki-
67 and BCL-2) and angiogenesis markers (VEGFR3 and CD31) and their effect on 
long-term survival of RCC patients. This study included 224 RCC patients who 
underwent nephrectomy between years 1985-1995 and were treated by same clinical 
practice. After this parallel TMAs were constructed for IHC analysis. 
All samples were positive for endothelial Ang2 expression, and Ang2 was expressed 
only in ECs, which is in line with our previous study (I) (Rautiola et al., 2016). In this 
work we developed an image-based quantification method of digital IHC signal, and 
the results were expressed as percentage of Ang2 positive area. Expression of Ang2 
positive area per total tissue area varied between 0.07 - 25.65%, and the median of 
Ang2 expression was 5.59%, which was used as a cut-off to categorize the samples 
into Ang2 high (>5%) and Ang2 low (≤5%) groups. Low Ang2 expression was 
detected 66.7% of the pRCC tumors, whereas high Ang2 expression was detected in 
52% of the ccRCC tumors.  
11.5. High Ang2 expression correlated with tumor grade, longer survival and low 
tumor cell proliferation (II) 
High Ang2 expression was associated (P = 0.04) with tumor grade: 1-2 (62%), 3 
(57%) and 4 (39%). Notably, very high Ang2 expression (top tertile, cut off 9.1% 
Ang2 positive area) correlated with longer survival. This is a very interesting result, 
challenging the current view that Ang2 promotes tumor progression, thereby 
predicting poor prognosis. As described before, and in our previous study (I) (Rautiola 
et al., 2016), tumor Ang2 may reflect Ang2 stored in endothelial Weibel-Palade bodies 
and may not correlate with the bioactive Ang2. However, it is interesting to speculate 
that Ang2 functions may be more complex, acting as an agonist in some tumors, and 
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as antagonist in others. The agonist activity might be regulated via tumor 
microenvironment associated factors, such as inflammation, and contribute to tumor 
vessel phenotype. 
Ang2 expression did not correlate with CD31 expression, but was correlated with high 
VEGFR3 (P = 0.004). High Ang2 expression was also correlated with low Ki-67 (P = 
0.032) and high BCL-2 (P = 0.012) expression. In univariate analysis, high Ki-67 
expression combined with both, low or high Ang2 expression, showed shorter OS than 
low Ki-67 and high Ang2. Instead, low BCL-2 expression was associated with shorter 
OS when combined with low or high Ang2 expression than high BCL-2 and low Ang2. 
Multivariate analysis showed shorter OS of patients with high Ki-67 and low Ang2 
expressions. Instead, combination of high Ang2, high Ki-67 and low BCL-2 predicted 
shorter OS. Virman et al. (2016) demonstrated using the same patient material that 
low BCL-2 and elevated Ki-67 were associated with poor prognosis. In addition, it has 
been demonstrated that RCC patients with high Ki-67 correlate with poor survival 
(Visapaa et al., 2003, Gayed et al., 2014). Also, our results are in line with previous 
results, demonstrating that low BCL-2 is associated with poor prognosis (Itoi et al., 
2004, Kallio et al., 2004).  
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 CONCLUSIONS 
Current anti-angiogenic drugs, which inhibit the growth of new blood vessels, have 
revolutionized the treatment of many human cancers, however, complete responses 
are rare, and most patients are either refractory or relapse after a few months of 
treatment. Furthermore, no clear guidelines exist for patient- or tumor-specific 
selection of anti-angiogenic therapeutic agents, and so far no established biomarkers 
for anti-angiogenic therapies are in clinical use. Therefore, novel treatment modalities 
for cancer are urgently needed, as well as knowledge of the biomarkers for the 
selection of patients, who will benefit from the anti-angiogenic therapy. Angiopoietin-
Tie system is a relevant and promising target for new anti-angiogenic therapies in 
cancer, but also, and perhaps more importantly in ocular neovascular eye diseases, and 
they also hold potential in many other vascular diseases, including 
inflammation/infection associated vascular leakage and diabetic vascular 
complications. Currently, the Ang2-targeted drugs are among the most advanced 
second-generation anti-angiogenic cancer therapies. However, the signalling 
mechanisms are poorly understood, and very little is known about Ang2 expression in 
human cancer. 
This study investigated the Ang-Tie growth factor receptor system from the molecular 
level to the translational level in order to better understand the function of the Ang-
Tie system in tumor angiogenesis and metastasis, and inflammation. Our results 
indicate that (1) orphan Tie1 is required for Ang-induced Tie receptor interaction, 
signalling, and Tie2 trafficking and (2) Tie1 is required for the agonist activity of Ang1 
and Ang2 in vivo during vascular remodelling. We also demonstrated that (3) Ang-
induced direct Tie1-Tie2 interaction in EC-EC contacts is dependent on β1-integrin, 
and that β1-integrin is required for Ang1 agonist activity. In addition, we showed that 
(4) anti-Ang2 Ab inhibits tumor growth and metastasis, and works at EC junctions to 
improve EC junction integrity during distant metastasis of the lungs. Moreover, we 
show that (5) the beneficial effects of the therapeutic anti-Ang2 Ab are likely mediated 
via internalization of Ang2-Tie2 protein complexes from the cell surface. 
At the translational level, we show in that (6) high Ang2 expression in the tumor 
vasculature alone or when combined with high CD31 expression was associated with 
high CBR, but not PFS or OS, whereas low Ki-67 expression was significantly 
associated with prolonged PFS and OS in patients treated with first-line sunitinib (I). 
In another study (II) we show that (7) very high Ang2 expression in RCC tumor 
vasculature was associated with prolonged OS in patients who received no targeted 
therapies. This result is surprising, as serum Ang2 has been considered a marker of 
poor prognosis in many cancers. 
Retrospective analysis of large patient cohorts from clinical trials would be 
informative to make conclusions about the potential of using Ang2 as a biomarker for 
anti-angiogenic or anti-Ang2 drugs. Furthermore, prospective analysis of large cohorts 
has the power to validate biomarkers identified in retrospective studies. Patient 
stratification based on clinical biomarkers should guide treatment decisions, and 
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thereby provide both clinical and economical benefit for the society. This research has 
uncovered several key questions about Ang-Tie biology and its function in the 
vascular endothelium, and shed light on the Ang-Tie expression in human cancer.  
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